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S U M M A R Y
C ongen ital adrenal hyperp lasia  (C A H ) is the com m onest adrenal d iso rder in 
ch ildhood (w orldw ide incidence is 1:14,554) and because it is po tentially  fatal, 
early  detection is necessary. M ass screening o f new born populations for o ther 
d is e a s e s , su ch  as c o n g e n ita l h y p o th y ro id ism , p h e n y lk e to n u r ia  and 
galactosaem ia, has been established based on blood sam ples collected  onto  filter 
paper (G uthrie cards). E levated concentrations o f the steroid, androstenedione 
(A 4 ), occur in untreated, classical cases o f CAH, and are m odestly  raised in late- 
onset cases. Som e increase m ay also  o ccu r in po lycystic  ovarian  disease. 
Several groups throughout the world have added screening (or pilo t screening 
studies) for 2 1 -hydroxylase defic iency , the m ost com m on form  o f  congenita l 
adrenal hyperplasia , to their existing neonatal program m es. From  1984, this 
w as the case in Scotland but, due to the lack o f central funding, screening was 
re luctan tly  stopped in 1986. The CA H screening program m es are based on the 
m easu rem en t o f  ano ther steroid, 17-hydroxyprogesterone (17-O H P), also 
elevated in untreated cases. How ever, A 4  determ ination offers greater potential 
as a d iagnostic aid because it also can detect the second m ost com m on form  o f 
C A H , 11 (3-hydroxylase defic iency . In addition, A 4  m easurem ent m ay be a 
better ind icato r o f the efficacy  o f g lucocortico id  rep lacem ent therapy in CAH 
patients than 17-OHP m easurem ent.
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U nfortunately , because m ost A 4 im m unoassaysare based on a tritiated label, they 
are cum bersom e, expensive and too insensitive to allow  m easurem ent in filter 
paper blood-spot sam ples. This m akes them  unsuitable for large-scale screening 
and hom e-m onitoring o f replacem ent therapy in patients with CAH.
T he aim  o f  this investigation  w as to  p roduce a sensitive, specific, precise and 
robust im m unoassay to m easure A 4  in serum  and blood elu ted  from  filter paper 
sam ples. A ntisera w ere raised in rabbits against A 4  linked to bovine serum  
album in (BSA ) at positions 3, 6  o r 11 on the steroid nucleus. G am m a-em itting  
labels w ere prepared by linking 125[i]_iQdohistam ine at positions 3, 6  o r 11 on 
the steroid nucleus. L inkages w ere through either carboxym ethyloxim e (CM O) 
o r hem isuccinate (HS) bridges. A m ajor part o f  the w ork involved the selection 
o f the best com bination o f  A 4  an tibody and A 4  label. Separation o f  antibody
bound and free fraction w as achieved by cen trifugation  o f m icroencapsu lated  
antibody or centrifugation after incubation with a second antibody.
A n an tiserum  ra ised  against A 4 -C M O -B SA  used w ith an A 4 - C M O - ^ 5 [  jj_ 
iodohistam ine tracer w as selected, on the basis o f  sensitiv ity  and specificity , as 
the best com bination  o f  reagents. T he perfo rm ance o f these reagen ts in an 
im m unoassay for A4  extracted from  serum  or eluates o f neonatal dried blood-spot 
sam ples was evaluated. A direct, non-extraction blood-spot im m unnoassay was 
also evaluated to facilitate large-scale screening for CAH. C oncentrations o f A 4 
in serum  under norm al and pathological conditions, such as C A H  and polycystic 
ovarian  d isease w ere investigated . A ndrostened ione w as m easured  in blood 
spots from  neonates born at term  o r p rem aturely , w ith re sp ira to ry  d istress 
syndrom e, o r with CAH.
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F o r the serum  assay, the range o f the standard curve w as 1-21 nmol/1 o f A 4 . 
T he coefficients o f variation o f the w ithin- and betw een-batches w ere <10%  for 
low , m edium  and high serum  pools. M ean analy tica l recovery  o f  tritia ted  
androstened ione o r un labelled  androstenedione, w hich had been added to sera 
b efo re  so lv en t ex tra c tio n , w as >95%  in bo th  cases. M easu rem en ts  o f 
an d ro s te n e d io n e  in d ilu tio n s  o f  sera from  p a tie n ts  w ith  in c reased  A 4 
concentrations exhibited parallelism  with the standard curve.
U sing  th is im m unnoassay , concen trations o f A 4  in patients ' sera show ed good 
agreem ent w ith concentrations found w ith the routine m ethod w hich em ploys a 
tritiated tracer. The correlation coefficient was 0.94 w ith a slope o f  1.02 and an 
in tercep t o f 0 .9  nmol/1 o f  A 4 . R esults for sam ples from  the U .K . N ational 
E xternal Q uality  A ssessm ent Schem e com pared  w ell w ith those from  the o ther 
partic ipating  laboratories. The bias was +12.2%  and the variability  o f  bias was 
6.9%  over a six m onth period.
Serum  androstenedione concentrations were sim ilar in m en and w om en and both 
groups show ed a reduction  w ith age. F or m en and w om en aged 18-40, the 
norm al range for A 4  (nmol/1) was 1.6-8.4 (x=5.(); n=78) and 0 .6 -8 .8  (x=4.7; 
n=70), respectively . F or m en and w om en aged 41-65, the norm al range was 
1 .2 -6 .6  (x=3.9; n=21) and 0 .9 -6 .8  (x=3.9; n=32), respec tive ly . D iurnal 
varia tion  in a group o f  norm al m ale volunteers was dem onstrated  by a m arked 
early  m orning  peak. A ndrostenedione concentrations w ere raised in sera from  
patients with CAH. They were grossly increased in an untreated neonate and in a 
tw elve-year-old  receiving inadequate steroid rep lacem ent therapy and m odestly  
raised in a late-onset case.
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M ean analy tica l recovery  o f  androstened ione from  neonata l blood spots was 
>99%  w ith or w ithout solvent extraction. F o r the ex traction and d irect blood- 
spot assays, the range o f the standard curves w as 4-525 and 5-300 nmol/1 o f A 4 , 
re sp ec tiv e ly . F o r fo u r q u ality  co n tro l b lood  spots, the m ean  in ter-a ssay  
coefficient o f variation was < 1 0  and <16%  and the m ean intra-assay was < 1 0  and 
<13% , using the extraction and direct m ethods, respectively.
T he norm al reference interval for androstenedione fo r infants born at term  was 
<4-22 and <5-88 nmol/1 with or w ithout solvent extraction, respectively. H igher 
concentrations o f A 4  were found in the direct assay than in the extraction m ethod. 
W hether m easuring directly  or after solvent ex traction , A 4  concentrations w ere 
ra ised  in som e sam ples from  infants born p rem aturely  o r w ho w ere suffering 
from  resp iratory  d istress syndrom e and in all cases o f CAH  (including one case 
o f  11 (3-hydroxylase deficiency).
T his thesis describes reagent production and perform ance o f  a sensitve, specific 
and robust radioim m unnoassay o f androstenedione em ploying  a [ ^ 5 j ]-labelled 
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a) percentage cross reaction in cross reaction studies
b) percentage o f total label bound in the construction o f dilution curves
c) percentage o f m axim um  label bound in the construction o f 
dose-response curves.
a) % C R =M ass o f steroid S required to displace 50%  o f labelled S X 100 
M ass o f steroid X required to displace 50% o f labelled S
b) % B /T=Bound labelled ligand (com) X 100 
total counts (cpm)
C) % B /B o=B ound labelled ligand (cpm l X 100 
M axim um  bound labelled ligand (cpm) 
(zero standard)
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AIM OF THIS STUDY
The aim  o f this study w as to produce an androstenedione antibody and a 
y-em itting androstenedione label suitable for a RIA  o f  androstenedione both in 
serum  and in eluates from  neonatal dried blood spot specim ens.
To achieve this, the m ain objectives were to:
1. Raise antisera in rabbits against a selection o f androstenedione conjugates.
2. Prepare a selection o f androstenedione radioligands.
3. C om pare different com binations o f label and antibody.
4. Test antisera for cross reactions with steroids sim ilar to androstenedione.
5. Select the best com bination o f label and antibody suitable for an 
androstenedione radioim m unoassay.
6 . D evelop a radioim m unoassay to m easure androstenedione in serum.
7. D evelop a radioim m unoassay to m easure androstenedione in dried blood 
spots.
8 . Evaluate the developed radioim m unoassays.
9. C om pare the serum  androstenedione results with the 'routine' serum  
radioim m unoassay based on a tritium  label.
10. C linically validate the developed radioim m unoassays.
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C H APTER 1 INTRODUCTION
1.1. T h e  A d r e n a l  G l a n d
1.1.1.  A n a t o m y
The adrenal glands are small paired, endocrine organs, w ith a com bined w eight 
o f 8 - 10 g in the adult. T hey are located above the k idneys (Fig. 1.), and are 
d iv ided  in to  a central portion  (m edulla), re sp o n sib le  fo r the p roduction  o f 
adrenaline and nor-adrenaline, and an outer portion (cortex), the site o f  synthesis 
o f  m ineralocortco ids, g lucocortico ids and adrenal androgens. There are three 
histologically defined zones o f the adrenal cortex, the zona glom erulosa, the zona 
fasciculata and the zona reticularis. In man, the outer zona glom erulosa consists 
o f islets o f  cells im m ediately  beneath the capsule, so that the underlying zona 
fascicu la ta  ex tends in num erous p laces to the capsule. T he zona fascicu la ta  
com prises the bulk  o f  the cortex  and consists  o f reg u la r co lum ns o f large, 
c h o le s te ro l- la d e n  c e lls  w h ich  a p p e a r  v a c u o la te d  u n d e r th e  lig h t
2 4
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m icroscope. The zona reticularis is the zone nearest the m edulla and consists o f 
s ligh tly  sm aller, m ore  com pac t ce lls. T he zona g lo m eru lo sa  spec ifica lly  
synthesises a ldosterone w hile the cells o f  both the zona fascicu la ta  and zona 
reticularis synthesise g lucocorto ids and androgens. It has been suggested 1 that 
the zona fasciculata and zona reticularis represen t d ifferent m orphological form s 
o f the same functional unit.
1 .1 .2 .  P h y s i o l o g y
T h e  c h ie f  a c tio n  o f  the  m in e ra lo c o r t ic o id s  (e .g . a ld o s te ro n e  and  
deoxycorticosterone) is on the kidney tubules, w here they prom ote the retention 
o f  sodium  (and w ater) and stim ulate  excretion  o f  po tassium . A ld o stero n e  
secre tion  is p rim arily  reg u la ted  v ia  the ren in -an g io ten sin  system , w hich is 
responsive  to  the blood volum e (F ig .2.). A ldosterone secretion  m ay also be 
stim ulated by serum  potassium  concentration and adrenocorticotrophic horm one 
(A C TH ).
T he g lucocortico ids (e.g. cortiso l and 11-deoxycortisol) p lay  a m ajo r ro le  in 
carbohydrate, protein and fat m etabolism . In addition, they are im portant in the 
body 's response  to stress, are an ti-in flam m ato ry  and can inh ib it the norm al 
im m uno log ica l response . C ortiso l enhances hepatic  g lu co n eo g en esis , the 
form ation  o f  g lucose from  non-carbohydra te  p recursors such as am ino  acids. 
This results initially in increased deposition o f glycogen in the liver. Any excess 
glucose synthesised enters the b loodstream  and m ay produce hyperg lycaem ia. 
C ortiso l also  an tagon ises the peripheral action o f insu lin  on g lucose uptake, 
enhancing hyperglycaem ia. The cortisol response to physical and physiological 
stress is extrem ely  im portant and, if absent, co llapse and even death m ay result 
from  circulatory failure.
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Fig. 2. Regulation of  aldosterone secretion,  
( t )  Increased. (4) Decreased.  ( 0 )  Inhibition.
The androgens are responsib le  fo r the developm ent o f phenotype and norm al 
sexual func tion  o f  the m ale. T he m ost abundan t c ircu la tin g  androgen  is 
dehydroepiandrosterone sulphate, w hich is alm ost exclusively  o f adrenal origin. 
The testes, and to a lesser ex ten t the ovaries, p roduce quantita tively  m ore C\ g  
an d ro g en s , in c lu d in g  an d ro s te n ed io n e  (A 4 ), and m inor am ounts o f  C4  g 
oestrogens than the adrenal co rtices o f  e ith e r sex. T he adrenal androgens, 
dehydroepiandrosterone, dehydroepiandrosterone sulphate and androstenedione 
have m in im al in trin sic  and rogen ic  ac tiv ity . H ow ever, they  co n trib u te  to 
and rogen ic ity  by their peripheral conversion  to the m ore po ten t androgens, 
testosterone and d ihydro testosterone. A lthough, dehydroep iandrosterone and 
d e h y d ro e p ia n d ro s te ro n e  su lp h a te  a re  s e c re te d  in g re a te r  q u a n ti t ie s ,  
an d ro s ten ed io n e  is q u a lita tiv e ly  m ore im p o rtan t, since it is m ore  read ily  
c o n v e r te d , p e r ip h e ra lly , to  te s to s te ro n e . In m a le s , c o n v e rs io n  o f  
an d ro sten ed io n e  to tes to stero n e  accoun ts fo r less than five p ercen t o f  the 
p roduc tion  ra te  o f  the la tte r horm one, and thus the p h y sio lo g ica l effec t is 
neglig ib le . In adult m ales, excess adrenal androgen secretion has no clin ical 
consequences; how ever, in boys it causes prem ature penile enlargem ent and early 
developm ent o f  secondary sexual characteristics. In fem ales, ovarian  androgen 
p roduction  is low , thus the adrenal substan tially  con tribu tes to total androgen  
p ro d u c tio n  by the p e rip h e ra l co n v e rs io n  o f  d eh y d ro e p ia n d ro s te ro n e  to  
androstenedione. A bnorm al adrenal function , resulting  in excess androgen , is 
m anifested by virilisation in females.
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1.1.3. Biosynthesis of Steroid Hormones
S tero id  horm ones are p roduced  from  cho leste ro l. C h o leste ro l s to rage , as 
cholesterol esters in lipid droplets, is contro lled  by the action o f  tw o opposing 
enzym es, cho lestero l esterase and cho leste ro l es te r syn thetase. In general, 
trophic horm ones, eg. A C TH , stim ulate the esterase and inhibit the synthetase, 
thus increasing the availability o f free cholesterol for steroid horm one synthesis.
A sim plified schem e o f  the steroid biosynthesis is shown in Fig. 3.
M ineralocorticoids
Pregnenolone, a A-5 steroid, is converted  to a bio logically  active A-4 steroid, 
p rogeste rone , by the 3 (3-hydroxystero id  d e h y d ro g en ase /iso m era se  en zy m e 
system . T he p ro g este ro n e  is then hyd ro x y la ted  at p o sitio n  21 to  form  
d e o x y c o r t ic o s te ro n e , an  a c tiv e  s o d iu m -re ta in in g  h o rm o n e . W h en  
deo xycorticosterone is hydroxy lated  at position  1 1 a  , co rticosterone, a w eak 
m ineralocorticoid  (but strong glucocorticoid), is form ed. C orticosterone is the 
precursor o f  aldosterone, the m ost potent sodium -retain ing horm one. Synthesis 
o f  a ld o s te ro n e  o ccu rs  in the zona g lo m eru lo sa , w h ile  the sy n th es is  o f  
corticosterone occurs further from  the capsule in the zona fascicu lata  and zona 
reticularis.
Glucocorticoids
G lucocortico id  synthesis requ ires hydroxy la tion  at position  17. 
P regnenolone and progesterone are converted  by 17-hydroxylase to
1 7 -h y d ro x y p reg n en o lo n e  and 1 7 -h y d ro x y p ro g es te ro n e , re sp ec tiv e ly . 
C o n v ersio n  o f  1 7 -h y d ro x y p reg n en o lo n e  to 1 7 -h y d ro x y p ro g este ro n e  is by 
enzym ic steps sim ilar to those that convert pregnenolone to progesterone.
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Fig. 3. A  sim plified schem e o f the traditional (and more recent) v iew  o f the 
b iosyn th esis o f  steroid horm ones. Roman numerals indicate enzym e 
reactions. (*) Principally in the testes and the ovaries.
1. 17, 20  desm olase (P450scc)
2. 17a-hydroxylase (P 450cl7 )
3. 1 7 ,2 0  lyase ( 44 )
4. 3 p-hydroxysteroid dehydrogenase
5. 2 1 -hydroxylase (P450c21)
6 . 11 P-hydroxylase (P450c 11)
7. 18-hydroxylase ( 44 )
8. 18-dehydrogenase ( 44 )
9 .*  17a-steroid dehydrogenase
10.* aromatase system (P450aro)
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^ - o o s r e p o e
W hen  17-hydrox y p ro g estero n e  und erg o es 2 1 -h y d ro x y la tio n , 11-d eo x co rtiso l is 
fo rm e d  an d  th is  is fu r th e r  h y d ro x y la te d  to  fo rm  c o r tiso l, th e  m o s t p o te n t 
g lu co co rtico id  in m an . P ara lle l h y d ro x y la tio n  steps o f  p ro g e s te ro n e  an d  17- 
hydroxyprogesterone resu lt in  corticosterone and cortiso l respectively .
Adrenal androgens
T he m ain  C4 9  s tero id  secre ted  by the adrenal co rtex  is d eh y d ro ep ian d ro s te ro n e . 
It is  p ro d u c e d  b y  th e  s id e -c h a in  c le a v a g e  o f  th e  C 2 1 s te ro id ,  17- 
h y d ro x y p r e g n e n o lo n e ,  b y  th e  a c t io n  o f  a 1 7 ,2 0  ly a s e  e n z y m e .  
D e h y d ro e p ia n d ro s te ro n e , a A -5 s te ro id  w ith  litt le  an d ro g e n ic  a c tiv ity , is 
co n v erted  to  a A -4 stero id , an d ro sten ed io n e , a m o d era te ly  ac tiv e  an d ro g en , by 
the 3 -(3 -h y d ro x y ste ro id  d e h y d ro g e n a se /iso m e ra se  e n z y m e  sy s tem . W h en  
androstened ione is reduced  at C -17, testo sterone is form ed.
A d v an ces  in  m o d em  p ro te in  ch e m is try  an d  the  ap p lic a tio n  o f  co n te m p o ra ry  
m o le c u la r  b io lo g y  h av e  c o m b in e d  to  a lte r  th e  ab o v e  tra d it io n a l v ie w  o f  
ste ro id o g en esis. U n d e rs tan d in g  o f  the  s te ro id o g en ic  en z y m e s  w as in h e re n tly  
lim ited  by in d ire c t m e th o d s  o f  in v e s tig a tio n  eg . m e a su re m e n t o f  s te ro id a l 
p recu rso rs  and  p ro d u c ts  in p a tien ts  o r  in c ru d e  sy stem s in  v itro . T h a t e a rlie r  
approach ind icated  each steroidogenic step w as m ediated  by m ultip le  enzym es that 
d iffe red  am o n g st the v ario u s s te ro id o g en ic  ce lls. T he  basic  s im p lic ity  o f  the 
system  w as only  app recia ted  w hen cD N A s and  genes w ere c loned . T h e  c lon ing  
w ork  has now  show n that the investigative  em phasis  in con tro l o f  stero idogenesis  
m ust be sh ifted  to the fine con tro l o f  a sm all n u m b er o f  m u lti-p u rp o se  en zy m es 
such as P 4 5 0 c l 1 and  P 4 5 0 c l7 .
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M o st s te ro id o g en ic  en zy m es are m em b ers  o f  th e  c y to ch ro m e  P 4 5 0  g ro u p  o f  
o x id ases  w h ich  co n ta in  a h em e g ro u p  an d  re d u ce  a tm o sp h e ric  o x y g en  w ith  
e lec trons from  N A D PH . The P 450  is the enzym e b ind ing  the ste ro ida l substra te  
and  m ed iating  the stero idal conversion  on an active site assoc ia ted  w ith  the  h em e 
group . M o st P 450  en zy m es can  m etab o lise  m u ltip le  su b s tra tes , c a ta ly s in g  a 
broad  array  o f  ox idations.
F o u r d istinc t P 4 5 0  enzym es are in v o lv ed  in  ad ren al s te ro id o g en es is^  an d  th e ir 
p o s itio n s  in  the  p a th w ay  are  show n  in  F ig u re  2. P 4 5 0 scc  is  the  s id e -ch a in  
c lea v ag e  en z y m e  m e d ia tin g  th e  se rie s  o f  re a c tio n s  fo rm e rly  te rm e d  2 0 ,2 2  
desm olase. P 4 5 0 c l l  m ed ia tes 11-hydroxy lase , 18 -hydroxy lase  and
18-m ethyloxidase activ ities. P 4 5 0 c l7  m ed iates bo th  1 7 a -h y d ro x y la se  and  
17,20 ly ase  ac tiv itie s . P 4 5 0 c2 1  m ed ia te s  th e  21 h y d ro x y la tio n s  o f  b o th  
g lucocortico ids and m inera loco rtico ids. In  the g onads (and  e lsew h ere) P 4 5 0 aro  
m ediates arom atisa tion  o f  androgens to  estrogens.
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1.1.4. Regulation of Adrenal Function
G lucocortico id  secretion  is con tro lled  by co rtico troph in  re leas in g  fac to r fro m  the 
hy p o th a lam u s v ia  ad ren o co rtico tro p h ic  ho rm o n e fro m  the an te rio r p itu ita ry . In  
ad d itio n  to  an in b u ilt c ircad ian  rh y th m , th e re  is a n eg a tiv e  fe ed b ac k  co n tro l, 
w h e reb y  c o r tic o tro p h in  re le a s in g  fa c to r, a d re n o c o r tic o tro p h ic  h o rm o n e  an d  
cortiso l secretions are  reduced  o r  inh ib ited  w hen p lasm a co rtico ste ro id  lev e ls  are 
too  h igh^  and  in creased  w hen  they  are in ap p ro p ria te ly  low , as show n  in  F ig .4 . 
W ith  re sp ec t to  reg u la tio n  an d  sec re tio n , the  zo n a  g lo m e ru lo sa  an d  th e  zo n a  
fa s ic u la ta  b eh av e  as tw o  sep a ra te  g lan d s. T h e  zo n a  fa sc ic u la ta  an d  zo n a  
re ticu la ris  are stim u la ted  by  ad ren o co rtico tro p h ic  h o rm o n e  to  sec re te  co rtiso l, 
corticosterone and  adrenal androgens, by  increasing  the conversion  o f  cho leste ro l 
to  p regn en o lo n e , w h ile  an g io ten sin  s tim u la tes a ld o ste ro n e  sec re tio n  by the zo n a  
g lo m e ru lo sa  w ith  a d re n o c o r tic o tro p h ic  h o rm o n e  p ro b a b ly  e x e r tin g  o n ly  a 
secondary  in fluence on the g lo m eru lar secretion  o f  a ld o ste ro n e^ - 6  (F ig .5 .). T he  
zona fa sc icu la ta  lacks the en zy m e necessary  fo r the  te rm in al step  o f  a ld o ste ro n e  
sy n thesis , w h ereas  th e  zo n a  g lo m eru lo sa  lack s  th e  1 7 a -h y d ro x y la s e  ac tiv ity  
requ ired  fo r the production  o f  17-hydroxycortico ids and  androgens.
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Fig. 4. Regulation o f glucocorticoid secretion. (— ) Stimulation. 
(— ) Inhibition. (CRF) Corticotrophin releasing factor.
(ACTH) Adrenocorticotrophic hormone.
Fig. 5. Regulation o f  steroid hormone biosynthesis assum ing the ‘two- 
gland’ theory. (— ) Stimulation. (— ) Inhibition. (ZG) Zona glomerulosa. 
(ZF) Zona fasciculata. (ZR) Zona reticularis. (DOC) Deoxycorticosterone. 
(D H E A ) Dehydroepiandrosterone. (17-O H -P) 17-Hydroxyprogesterone. 


































1.1.5. The Fetal Adrenal Gland
Anatom y
T he adrenal g lands o f  the fe tu s g row  rap id ly  and  by the en d  o f  the  firs t tr im este r 
are equal to  o r g reater than the size o f  the fetal k idney^ . A pprox im ate ly  fifty  
p ercen t o f  fe ta l ad renal m ass co n sis ts  o f  an  in n e r fe ta l zone  co m p o sed  o f  large , 
oesin o p h ilic  ce lls  p ro d u c in g  A-5 stero ids. T he fe ta l zone is su rro u n d ed  b y  the  
o u ter, d e f in itiv e  o r  ad u lt zo n e  w h ich  is c o m p o sed  o f  sm all, b a so p h ilic  c e lls  
resem bling  those o f  the adult zona g lom eru losa . T h e  fe ta l zo n e  a tro p h ies  w ith in  
th ree  m on ths a fte r b irth . D u rin g  the n ex t th ree  y ears , the ad u lt ad ren a l co rtex  
develops from  the ou ter layer o f  the cortex  and d ifferen tia tes in to  the th ree  adrenal 
zones, zona glom erulosa, zona fascicu la ta  and zona re ticu laris.
Physiology
T h ere  is fu n c tio n a l sp ec ia lisa tio n  o f  the  fe ta l an d  d e fin itiv e  zo n es o f  the  fe ta l 
adrenal g lan d P  bo th  o f  w h ich  are s tim u la ted  by  ad ren o co rtico tro p h ic  h o rm one. 
T he  d efin itiv e  zone p ro d u ces p rim arily  co rtico id s , in c lu d in g  m o st fe ta l co rtiso l. 
T he fe ta l zone is unab le  to  p ro d u ce  co rtiso l d u e  to  a d e fic ien cy  o r  b lo ck  o f  the  
ste ro id  3 ( i-h y d ro x y s te ro id  d e h y d ro g e n a se  e n z y m e  s y s te m .9 It p ro d u ces , 
h o w ev er, d e h y d ro e p ia n d ro s te ro n e  su lp h a te  an d  o th e r  A-5 s te ro id s . F e ta l 
d eh y d ro ep ian d ro ste ro n e  su lphate  is h y d ro x y la ted  a t C -1 6  by  th e  fe ta l liv e r and  
transported  to  the  p lacen ta  w here  it is d esu lfa ted  befo re  a ro m a tisa to n  to  oestrio l. 
M a te rn a l d e h y ro e p ia n d ro s te ro n e  su lp h a te  e i th e r  fo llo w s  th is  ro u te ,  o r  is 
tran sp o rted  to  the p lacen ta  to  be d esu lfa ted  and  co n v e rted  by  en zy m ic  p a th w ay s  
co m m o n  to  s te ro id -p ro d u c in g  tis su e s  to  a n d ro s te n e d io n e  an d  te s to s te ro n e . 
T h ese  an d ro g en s  are  a ro m a tised  by  th e  p la c e n ta  to  o e s tro n e  an d  o e s tra d io l, 
respectively . 10
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1.2. C o n g e n i t a l  A d r e n a l  H y p e r l a s i a  (C A H )
T he co m m o n est ad renal d isease  in in fan cy  and  ch ild h o o d  is C A H . It w as firs t 
d esc rib ed ^ ! in c lin ical and p a th o lo g ica l de ta il in  1865, b u t the  p a th o p h y sio lo g y  
w as no t und ers to o d  un til 1 9 5 0 .12’13 C A H  is an in h erited  d efic ien cy  o f  o n e  o f  
the en zy m es n ec essa ry  fo r the  b io sy n th e s is  o f  th e  p rin c ip a l ad ren a l s te ro id , 
cortisol. D ecreased  cortiso l secretion resu lts in un inh ib ited  adrenocortico troph ic  
ho rm o n e sec re tio n  fro m  the  p itu ita ry  (F ig .6 .) fu r th e r  s tim u la tin g  th e  ad ren a l 
cortex lead ing  to oversecretion  o f  steroids before the enzym e block.
A  n u m b er o f  in b o rn  e rro rs  o f  s te ro id  b io sy n th es is , c h a rac te rised  o v e r  th e  la s t 
tw en ty  y ea rs , a re  show n  in  T ab le  1. O n ly  th e  21- an d  1 l p - h y d r o x y l a s e  
d efic ien c ies  w ill be d iscu ssed  fu rth e r, as th ey  re p re se n t n in e ty -f iv e  an d  fo u r 
percen t, re sp ec tiv e ly  o f  to ta l C A H  cases. T h e  o th e r d e fic ien c ies , re p resen tin g  
one p ercen t o f  to tal C A H  cases, are ra re  and  o ccu r on ly  as s ing le  case  s tu d ies  in 
the literature.
1.2.1. 21-H ydroxylase Deficiency
Im p a irm en t o f  2 1 -h y d ro x y la tio n  is  th e  m o s t co m m o n  en z y m a tic  d e f ic ie n c y  in 
C A H . T he  m ost p ro m in en t featu re  o f  21 -h y d ro x y lase  d e fic ien cy  in the  n eo n a te  
is v irilisa tio n  o f  the  fem ale  gen ita lia . M ales w ith  th is  en zy m e  d e fec t m ay  no t 
m an ife s t o b v io u s  g en ita l ab n o rm a litie s  a t b ir th , b u t w ith o u t tre a tm e n t w ill 
m anifest p rogressive  v irilisa tion  w ith p recocious puberty  and  advanced  bone age.
3 2
neural




d ftte r io r 
p i t u i ta r y
Adrenal cortex
Fig. 6. Loss o f cortisol feedback inhibition mechanism in 
congenital adrenal hyperplasia. (— ) Overstimulation.
( / / )  Enzyme block. (— ) Stimulation. (CRF) Corticotrophin
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A drenocortica l function  begins in  the th ird  m on th  o f  g esta tio n , a c ritica l tim e fo r 
sexual d ifferen tia tion . I f  at th is tim e, fem ale  fe tu ses are  ex p o sed  to  h igh  levels  
o f  and rogen , as in  C A H , they  w ill m an ife st v irilisa tio n  o f  th e  ex te rn a l g en ita lia  
bu t h av e  a n o rm al re p ro d u c tiv e  trac t. 14 In  th e  m ale , the n o rm al so u rce  o f  
androgen  is the fe ta l testis, bu t and rogen  fro m  the ad ren al o r ex o g en o u s  sou rces 
can cause subtle changes o f  the ex ternal gen ita lia  eg. p igm en tation  o f  the scro tum  
o r slight en largem ent o f  the penis.
A  sa lt-w astin g  fo rm  o f  C A H  is fo u n d  in  ap p ro x im a te ly  fif ty  to  sev e n ty -fiv e  
p ercen t o f  the  cases o f  2 1 -h y d ro x y lase  d efic ien cy . In  ad d itio n  to  v irilisa tio n , 
th e re  is p ro fo u n d  a ld o s te ro n e  d e f ic ie n c y . T h is  s a lt-w a s tin g  fo rm  o f  21- 
h ydroxy lase  C A H  m ay  p resen t w ith  a life -th rea ten in g  c ris is  w ith in  the  firs t few  
w eek s o f  life  and , th e re fo re , m u st b e  re c o g n ise d  so o n  a f te r  b ir th  to  a llo w  
replacem ent therapy to be initiated.
A  hypothesis to  explain  w hy som e cases o f  C A H  are sa lt-w asting  w hile  o th ers are 
o n ly  v ir ilis in g  h as been  recen tly  s u g g e s te d . 15 i t  s ta tes  th a t in  b o th  s im p le  
v irilisers and salt-w asters, there is a fascicu la ta  d efec t o f  2 1 -hydroxy la tion  in  both  
the 17-hydroxy and  17-deoxy pathw ays. H o w ev er, in the sa lt-w aste r th ere  is a 
d efec t in 2 1 -hy d ro x y la tio n  in  the g lo m eru lo sa , w h ile  in th e  s im p le  v ir ilise r  the  
g lom eru losa is spared this defect (F ig .7 .), thus a llow ing  no rm al m in era lo co rtico id  
production .
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Fig. 7. Pathway o f steroid biosynthesis in the sim ple-virilising (S.V .) 
and salt-wasting (S.W .) forms o f congenital adrenal hyperplasia 
due to 21 -hydroxylase deficiency.
(=) Enzym e block. (*) 21-hyroxylase enzym e.
(ACTH) Adrenocorticotrophic hormone.
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N on c la ss ica l sy m p to m atic  (la te -o n se t) C A H  is a sy m p to m  c h a ra c te r is e d  by  
v irilisa tion , m enstrual d istu rbances and  end o crin o lo g ica l fea tu res  co n sis ten t w ith  
2 1 -h y d ro x y lase  d efic ien cy  that p resen ts  in  la te r ch ild h o o d  o r  a d o le s e n c e ! 6 - 1 8  
U nlike  fem ales b o m  w ith  classica l 2 1 -hydroxy lase  defic ien cy , fem a les  w ith  late- 
onset 2 1 -hydroxylase defic iency  dem onstra te  no  ev idence o f  v irilisa tio n  in  u tero . 
B oth types o f  patients respond  sim ilarly  to  g lucocortico id  treatm ent.
T he late presentation  o f  a b iochem ical defect has ra ised  the question  as to  w h e th e r 
th is is the sam e in h erited  d iso rd e r as C A H  w ith  d e lay e d  p re sen ta tio n , o r  is an  
aqu ired  d iso rd er d istinc t from  C A H . T h ere  is a c lo se  g en e tic  lin k ag e  b e tw een  
the  g en e  re sp o n s ib le  fo r  2 1 -h y d ro x y la se  d e f ic ie n c y  a n d  H L A , th e  m a jo r  
h is to co m p atab ility  co m p lex  in  hu m an s 19,20 R ep o rts  h av e  p ro v id ed  ev id en ce  
that late-onset C A H  is in  fact a lso  genetically  linked  to H L A 2 !"2 ^ an(j h  has been 
p ro p o sed  th a t c la ss ica l an d  la te -o n se t 2 1 -h y d ro x y la se  d e f ic ie n c ie s  a re  a lle lic  
v a r i a n t s .  ’^ 2 ,23  j n patien ts  w ith  cry p tic  2 1 -h y d ro x y lase  d efic ien cy , h o rm o n al 
abnorm alities are sim ilar to late-onset bu t w ithout clin ical stigm ata.
1.2.2. lip -H y d ro x y la se  D eficiency
C A H  du e  to 1 ip -h y d ro x y la s e  d e fic ien cy  is  a m u ch  ra re r  d is o rd e r  th an  
2 1 -h y d ro x y lase  d efic ien cy , acco u n tin g  fo r  ap p ro x im a te ly  fo u r  p e rc e n t o f  all 
C A H  cases  d ia g n o s e d .2 4 - 2 6  T h is  fo rm  o f  C A H  w as re co g n ised  in  th e  ea rly  
1950 's by the p re sen ce  o f  h y p erten s io n  in  ad d itio n  to  v ir il is a tio n .2 7 »28 T h e  
d efec t in 11 p -h y d ro x y la tio n  in an affec ted  in d iv id u a l w as d em o n s tra te d 2 9 >30 
severa l y ears  later. S u b seq u en t re p o r ts ^ 1 _34  h av e  fu r th e r  d o c u m e n te d  th e  
clinical and biochem ical abnorm alities in such patients.
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A n 1 1 (3-hydroxylase d efec t in  the zo n a  fa s icu la ta  re su lts  in d ec rea sed  co rtiso l 
b io sy n th es is  and  in d u c tio n  o f  ad ren o co rtico tro p h ic  h o rm o n e  h y p e rse c re tio n , 
w hich  in turn , causes overp ro d u ctio n  o f  an d ro g en s an d  ste ro id  p recu rso rs  p rio r 
to  the en zy m e b lock , no tab ly  1 1 -deoxycortiso l an d  d eo x y co rtico s te ro n e . T h e  
latter steroid  is reponsib le  fo r the hypertension  fe a tu r e .3 5 -3 7  T he en zy m e is a lso  
n e c e s s a ry  in  th e  z o n a  g lo m e ru lo s a  to  c o n v e r t  d e o x y c o r t ic o s te ro n e  to  
co rticoste rone and h y poaldosteron ism  can usually  be d o cu m en ted  b io ch em ica lly  
b u t is a sy m p to m atic .38 T he  cause  o f  h y p o a ld o s te ro n ism  can n o t be a ttrib u ted  
exclusively  to  a b iosynthetic  block, but is a lso  secondary  to  the suppression  o f  the 
r e n in - a n g i o t e n s i n  s y s te m  b y  th e  m i n e r a lo c o r t i c o i d  e f f e c t  o f
d eoxycorticosterone .39,40
V irilisation  is found  in affected  ind iv iduals  and  resu lts  fro m  an o v erp ro d u ctio n  o f  
and ro sten ed io n e  w ith  en h an ced  co n v ersio n  to  te s to s te ro n e .4 1 ,4 2  T h e  lev els  o f  
these  androgens are sim ilar to  those  fo u n d  in 2 1 -h y d ro x y lase  d e f ic ie n c y .43 
A s w ith  21-hydroxylase defic iency , m ascu lin isa tion  o f  the fem ale  gen ita lia  before  
b irth  is du e  to  the e ffec t o f  in creased  an d ro g en s ea rly  in  g esta tio n , w h en  sexua l 
d ifferen tiation  occurs.
C A H  du e  to  11 (3 -h y d ro x y la se  d e f ic ie n c y  is  a h e te ro g e n e o u s  d is o rd e r  an d  
co n sists  o f  a n u m b er o f  ab e rra tio n s  w ith  d iffe ren t c lin ica l ex p ress io n s . T h e  
ran g e  is w ide and  at on e  en d  o f  the  sp ec tru m  is  the c la ss ica l co n g e n ita l d e fec t 
w hich  is usually  detec tab le very early  in life by  p ron o u n ced  v irilisa tion  w ith44-48  
o r w ith o u t h y p erten s io n .4 2 ,4 9 ,5 0  A t the  o th er ex trem e  ex is ts  the  la te -o n se t 
fo rm s o f  th e  d iso rd e r , d e sc r ib e d  in  p o s t-m e n a rc h a l fe m a le s  w h o se  o n ly  
com plain ts have been hirsu tism  and m enstrual d istu rbances.51 -53
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Such clin ical variab ility  m ay be the expression  o f  a single genetic d e fec t in w hich  
d iffe ren t a lle les exp ress v ary in g  deg rees o f  en zy m ic  d efic ien cy , as is the  case  in  
2 1 -h y d ro x y la se  d e f ic ie n c y .2 4 ’2 5 ’5 4  H o w ev er, the 11 (3 -h y d ro x y la tio n  step  is 
q u ite  co m p lica ted , re q u ir in g  sev e ra l en z y m e s  an d  c o fa c to rs ; th u s  sev e ra l 
m u ta tio n s are  p o ss ib le .2 5 ’5 5  T h ese  m ay  acco u n t fo r  th e  c lin ica l h e te ro g en e ity  
observed  in patien ts w ith this defect.
1.2.3. Treatment of CAH
T reatm ent o f  C A H  is sim ple, effec tive and  cheap . S ince  1949, w h en  the efficacy  
o f  co rtisone therapy  in  C A H  w as d isco v ered , 12 »5 ^  g lu co co rtico id  re p lacem en t 
has been the  k ey sto n e  o f  trea tm en t. S a lt-re ta in in g  ste ro id s h av e  b een  u sed  in  
addition to  g lucocortico ids in the salt-w asting  fo rm  o f  the d isorder.
D e f i c i e n c y  o f  b o th  c o r t i s o l  a n d  a l d o s t e r o n e  r e s u l t s  in  
h y p o n a tra e m ia /h y p e rk a la e m ia  le a d in g  to  fe e d in g  d if f ic u l t ie s ,  v o m itin g , 
dehydration  and  p erip h e ra l c ircu la to ry  co llapse . T h is  sa lt-lo sin g  c ris is  req u ires  
im m ed ia te  tre a tm e n t w ith  in tra v e n o u s  sa lin e  an d  d e x tro se . C o r tiso l an d  
m ineralocorticoid  rep lacem ent therapy is required . P lasm a adm in istra tion  m ay  be 
n e c e s sa ry  i f  th e re  is  p e r ip h e ra l  c irc u la to ry  f a i lu r e .5 2  T h e  am o u n t o f  
m in era lo c o rtic o id , and  the  co n c e n tra tio n  an d  am o u n t o f  sa lin e  so lu tio n  are  
ad ju s ted  ac co rd in g  to  the  re su lts  o f  fre q u e n t e le c tro ly te  d e te rm in a tio n  an d  
assessm ent o f  the state o f  hydra tion  and  b lood  p ressu re  m easu rem en ts .5 ^ L o n g  
term  rep lacem en t th erap y  is req u ired  to  m ain ta in  su ffic ien t g lu co co rtic o id  and  
m in era lo c o rtic o id  ( if  n ecessa ry ) to  a llow  n o rm al g ro w th  d u rin g  in fa n c y  an d  
childhood, prepubertal developm ent, and adult rep roductive  po ten tial.
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T herapuetic  co n tro l is m on ito red  by c lin ica l and  b io ch em ica l p a ram ete rs . T he  
fo rm er includes serial m easurem ents o f  grow th  v e loc ity  and  skeleta l age, signs o f  
co rtiso lism , age at o n se t o f  puberta l s tages, and  reg u la rity  o f  m en ses  in  the p o st 
m en arch a l fem a le . S ev era l m o n ito rs  h av e  b een  a sse sse d  in  an  a tte m p t to  
d e te rm in e  the co rrec t leve l o f  rep lacem en t therapy . M easu rem en ts  o f  ad ren al 
steroid precursors in  plasm a, advocated  as an index  o f  therapeu tic  con tro l, include 
1 7 -h y d ro x p ro g es te ro n e 5 9  and  a n d ro s te n e d io n e .^  T h is  asp ec t is d iscu ssed  
la ter in re la tion  to an androstenedione b lood  spot assay.
Surg ical co rrec tion  o f  the v irilised  fem ale  gen ita lia  is u sua lly  p erfo rm ed  be tw een  
six and  tw elv e  m o n th s o f  age. In p a tien ts  w ith  2 1 -h y d ro x y la se  d e fic ien cy , 
fe rtility  in  m ales, and fem in isa tion , m en stru a tio n  and  fe rtility  in  fem a les  can  be 
ex p ec ted  w ith  ad eq u a te  trea tm en t. L o n g -te rm  p sy c h o lo g ic a l g u id a n c e  an d  
support fo r the patien t and  fam ily  by the physic ian  is essential.
1 .2 .4 . Incidence o f  C A H
T he p rev a len ce  o f  C A H  ap p ea rs  to  v a ry  c o n s id e rab ly  th ro u g h o u t th e  w o rld . 
S ince 1956, es tim atio n s o f  the in c id en ce  o f  C A H  b ase d  on  ca se  su rv ey s  h av e  
v aried  be tw een  1:490 in  the  Y u p ik  E sk im o s o f  so u th  w e ste rn  A la sk a ^  1 to 
1 :67,000 in the M ary lan d , U S  A . 62 H ig h  in c id en ces  w ere  re p o rted  in  the  a rea  
a round  R om e (1 :5 ,5 8 0 )6 3 , Z urich  (1 :5 ,0 4 1 )6 4 , M u n ich  (1 :9 ,8 3 1 )6 5  an d  th e  
A u s tria n  T y ro l ( 1 :8 ,9 9 1 ) 6 6 . T h e  in c id en c e  o f  C A H  in  B irm in g h a m  w as 
estim ated ,67 o v e r a ten year period , to be 1:7,255.
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F rom  1 9 7 8  neonatal screening p rogram m es o r p ilo t stud ies have been  estab lished  
n a tio n a lly  o r  reg io n a lly . T he in c id en ces  o f  C A H , as d e te rm in e d  by m o st 
screen ing  p rog ram m es, w ere h ig h er than  those  rep o rted  by case  s tu d y .6 1 ,6 8 ,6 9  
In 1 9 8 8  P ang  et  al  reported  a w orldw ide incidence o f  1 :1 4 ,5 5 4  fo r c lassica l C A H  
d etec ted  by screen ing  p ro g ram m es in  several c o u n tr ie s 7  0  (> 1 m illio n  n eo n a tes  
w ere screened  betw een  1 9 8 0  and 1 9 8 8 ) . E x c lu d ed  fro m  th is fig u re  w ere  tw o  
popu lations the occu rren ce  o f  C A H  is very  m uch  g reater. T h ese  are the  Y u p ik  
E sk im os and the  peop le  o f  L a  R eun ion , F ran ce  w h ere  the  in c id en ce  o f  C A H  is 
1 :2 8 2 7 1  and  1 :2 ,1 4 1 , 6 9  re sp ec tiv e ly . In  S co tlan d , b e tw een  1 9 8 4  an  1 9 8 6 , a 
n a tio n a l n eo n a ta l sc reen in g  p ro g ram m e  fo r  C A H  re v e a le d  a p re v a le n c e  o f  
1 :1 7 ,0 9 8 ^ 8  T his w as h igher than  1 :2 0 ,9 0 7  ob ta in ed  in  a re tro sp ec tiv e  S co ttish  
stu d y .6 8  in  the U SA , screen ing  fo r C A H  is un d ertak en  in  several states. In 
June 1 9 8 9 , T exas began  screen ing  its n ew b o rn  p o p u la tio n  ( 2 ,5 0 0  sam p les/d ay ) 
fo r C A H .7 2  T hese figures, sum m arised  in T ab le  2 , app ly  a lm o st ex c lu siv e ly  
to the 2 1 -hydroxy lase  defic iency ; the o th er en zy m e d efec ts  are  v ery  m u ch  ra rer, 
and appear on ly  as sing le case  repo rts . S u r v e y s 8 5  in  Israe l h av e  re v ea led  an 
unusually  h igh  inc idence  o f  C A H  in  genera l, bu t p a rticu la rly  o f  the  
1 ip -h y d ro x y la se  defec t am o n g  the Jew s o f  N o rth  A frican  o rig in . A s w ith  the  
E skim o population , this high incidence m ay  be re la ted  to  consanguin ity .
Several popu lation  studies have estab lished  that the 21-hydroxy lase  defic iency  is
tran sm itted  as an  au to so m al re ce ss iv e  tra it ,6 2 ,6 4 ,8 6  w jth m a les  an d  fem a les
eq u a lly  at r is k .8 7  T h is  w as b o rn e  o u t by  the  w o rld w id e  C A H  sc reen in g
ex p e rie n c e 7 ^  and a case  survey  o f  80 ch ild ren  w ith  C A H , co n d u c ted  b e tw een
1968 and 1988, by D o n a ld so n  et  al  w ho  fo u n d  the  m ale  to  fem a le  ra tio  to  be 
1:1.88
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Table 2. M ean incidence o f congenital adrenal hyperplasia.
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West Germany, Munich 1: 9,831 (77)65

















New' Zealand 1:16,258 (87)75



































( ) Y ear o f  publication. (+) D onaldson, M D  C 1990-personal com m unication .
E ith e r the  sim p le  v irilis in g  o r sa lt-w astin g  fo rm  is fo u n d  a lm o s t c o n s is ten tly  
w ith in  one fam ily , w ith  the sa lt-w asting  fo rm  o ccu rrin g  in  abou t a th ird  to  a h a lf  
o f  the p a tien ts  w ith  2 1 -hydroxy lase  d e fic ien cy .8 9  H o w ev er, m o re  recen tly , in 
d e te rm in in g  the  w o rld w id e  p re v a len ce  o f  C A H  by sc reen in g , a  77%  re la tiv e  
incidence is show n fo r salt-w asting  hyperp lasia  and  23%  fo r sim p le  v ir i l i s in g 7 0
1.2.5. Screening for CAH
A s a re su lt o f  e lec tro ly te  im balance  and  c ircu la to ry  fa ilu re , C A H  m ay  h av e  fa ta l 
consequences i f  it is no t trea ted . C h ild ren  w ith  p artia l d e f ic ien c ie s  m ay  n o t be 
iden tified  fo r several years.9^  T he  trea tm en t o f  C A H  by o ra l ad m in is tra tio n  o f  
g lucocortico ids and  m inera locortico id , i f  requ ired , is sim ple , ch eap  an d  effec tive . 
T hese facto rs, in  con junction  w ith  the re la tiv e ly  h igh  in c id en ce , m ee t the  c rite ria  
p roposed  fo r the in stitu tion  o f  a screen ing  p ro g ram m e .9 ! S ev era l g ro u p s h av e  
p ro p o sed 9 ^"9 ^ th a t all n ew born  in fan ts  shou ld  be screened  fo r 2 1 -h y d ro x y la se  
defic iency , since both  c lassica l and n o n -c lass ica l types have  go n e  u n reco g n ised . 
M ore recen tly , P an g  e t al co n firm ed  th a t n ew b o rn  sc reen in g  im p ro v ed  o v era ll 
case detec tion  o f  C A H  w orldw ide and  im p ro v ed  case  d e tec tio n  o f  new b o rn s w ith  
the sa lt-w astin g  fo rm  o f  C A H  w h o se  d iag n o s is  p re v io u s ly  m ig h t h av e  b een  
m issed , resu lting  in dea th .70
E arly  d iag n o s is  by c lin ica l o b se rv a tio n  is  c o n firm e d  by th e  m e a su re m e n t o f  
ad renal s tero id  p recu rso rs  in p lasm a an d /o r ad ren al s te ro id  m e tab o lite s  in u rine . 
D e ta ile d  u rin a ry  p ro f ile s  o f  s te ro id  m e ta b o li te s  b y  c a p il la ry  g as  c o lu m n  
chrom atography provide defin itive inform ation  as to the site o f  en zy m e defects  in
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neonates w ith  C A H .9 5 ,9 6  Such m easu rem en ts  are su p erio r to  th o se  o f  u rin ary  
stero id  m etabolites by  conventional gas liqu id  ch ro m ato g rap h y  and  ca lcu la tio n  o f  
th e  1 1 -o x y g e n a tio n  in d e x .97  T he  m o st w id e ly  a c cep ted  m a rk e r  o f  the  21- 
hyd ro x y lase  d efic ien cy  is an e lev a ted  p lasm a 1 7 -h y d ro x y p ro g es te ro n e  le v e l .5 7  
E arly  m e t h o d s ^ , 9 9  fo r  m easu rin g  1 7 -h y d ro x y p ro g e s te ro n e  re lie d  on  th e  
ex trac tio n  o f  the  s te ro id  fro m  th e  p la sm a  fo llo w ed  b y  a c o m p e titiv e  p ro te in  
b in d in g  assay . R ad io im m u n o a ssa y  h as  n o w  re p la c e d  c o m p e tit iv e  p ro te in  
b in d in g  m e th o d s  b e c a u s e  o f  i ts  b e t te r  s e n s i t iv i ty ,  p r e c i s io n  a n d  
s p e c i f i c i t y .  100 ,101  T h e  d ev e lo p m en t o f  a m ic ro -f ilte r  p a p e r  m e th o d 9 2  fo r 
m easu rin g  1 7 -h y d ro x y p ro g estero n e  and  the in tro d u c tio n  o f  l ^ 5 [I]-lab e l m ad e  
possib le m ass neonatal screen ing  fo r C A H . T his m ethod  u tilises a heel p rick  fo r 
o b ta in in g  a c ap illa ry  b lo o d  sp ec im en  to  sp o t o n to  f i l te r  p a p e r  w h ich  is th en  
analysed  fo r 1 7 -h ydroxyprogesterone by  R IA . T h e  h o rm o n e  is  s tab le  on  filte r  
p ap e r an d  the f ilte r  p ap e r sp ec im en s can  be sen t to  th e  sc reen in g  lab o ra to ry  
through the postal system .
A lthough  17-hydroxyprogesterone levels are g rossly  e lev a ted  in  2 1 -h y d ro x y la se  
d efic iency , they  m ay be o n ly  m o d estly  ra ise d  in  the  less  co m m o n  
11 (3-hydroxylase b l o c k .  102 T herefo re , m easu rem en t o f  17 -hy d ro x y p ro g estero n e  
m ay  n o t s e le c t  c a s e s  o f  C A H  d u e  to  1 l ( 3 - h y d r o x y la s e  d e f i c i e n c y .  
A n d ro s ten ed io n e  lev e ls  h av e  been  show n to  be g ro ss ly  e lev a ted  in  b o th  11(3- 
h ydroxy lase  and  2 1 -hydroxy lase  enzym e d e f i c i e n c i e s  103,104  an(j m ay th ere fo re  
o ffer greater po ten tial as a d iagnostic aid.
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Prenatal Diagnosis
T he 2 1 -hydroxylase gene is located  on  ch rom osom e 6 , be tw een  the H L A -A  locus 
and  the cen tro m ere . 105 T his o b serv a tio n  h as  been  used  to  ad v a n ta g e  in the  
d e te c tio n  o f  h e te ro z y g o te s  10 6  fo r  2 1 -h y d ro x y la se  d e f ic ie n c y , c l in ic a lly  
unrecogn ised  hom ozygotes and  fo r p renata l d iagnosis. 107
H L A  g en o ty p in g  o f  am nio tic  ce lls  co llec ted  fro m  p re g n an c ie s  a t r isk  has been  
s u c c e s s fu l in  th e  p re n a ta l  d ia g n o s is  o f  C A H  d u e  to  2 1 -h y d ro x y la s e  
d e f ic i e n c y .^08 H o w ev er, th is is a co m p lex  an d  tim e -co n su m in g  m e th o d  and  
does no t d e tec t C A H  du e  to  11 p -h y d ro x y la se  d e fic ien cy  b ecau se  c lo se  g en e tic  
linkage betw een  the gene re sp o n sib le  fo r  11 p -h y d ro x y la se  d e fic ien cy  an d  H L A  
has not been estab lished  in  this fo rm  o f  C A H . 109 A t p resen t, the  d efin itiv e  test 
fo r the p ren ata l d e tec tion  o f  th is d iso rd e r is the  m easu rem en t o f  
17-hydroxyprogesterone concentrations in m id -trim ester am nio tic  f lu id . 110-112
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1.3. R a d i o i m m u n o a s s a y
In 1977, a re liab le  screen ing  test fo r C A H  becam e av a ila b le .9 2  T h is  w as b ased  
on a m icro  f ilte r  p ap e r m eth o d  o f  R IA  fo r 1 7 -h y d ro x y p ro g es te ro n e . R IA  is 
based  on  saturation  analysis and has m ade po ssib le  the m easu rem en t o f  ve ry  low  
levels (pg) o f  h o rm ones w ith  a h igh  d eg ree  o f  sen sitiv ity  an d  sp ec ific ity . T h is  
elegan t p ro ced u re  w as firs t rep o rted  in 1960 w hen  d e ta ils  o f  a  th y ro x in e  assay  
using  th y ro x in e-b in d in g  g lobu lin  w ere p u b lish ed  113 an d a p la sm a  in su lin  R IA  
w as described . 114 T he  basis  o f  sa tu ra tion  an a ly sis  is the  co m p e titio n  b e tw een  
lab e lled  an d  u n lab e lled  fo rm s o f  the  lig an d  fo r sp ec if ic  s ite s  o n  the
an tib o d y . T h e  am o u n t o f  la b e lle d  lig a n d  b o u n d  to  a n tib o d y  is  in v e rse ly
proportional to  the w eigh t o f  un labelled  ligand  present.
T h e  req u irem en ts  fo r an y  R IA  p ro c ed u re  a re  a sp ec if ic  a n tib o d y , a la b e lle d  
an tigen  and  a m ean s o f  sep ara tio n  o f  an tibody  b o u n d  and  free  frac tio n s . T h ese  
req u irem en ts  are  d iscu ssed  below  w ith  spec ia l re fe ren ce  to  the  m easu rem en t o f  
stero ids by R IA .
1.3.1. Antibody Production
T h e  ab ility  o f  the  im m u n e  sy stem  to  re sp o n d  to  an  an tig en  is d e p e n d e n t o n  
m o le c u la r  size. M o lecu le s  w ith  m o le c u la r  w e ig h ts  b e lo w  6 ,0 0 0  are  p o o r  
an tig en s. S te ro id s  are  sm all (m o lec u la r w e ig h ts  a p p ro x im a te ly  3 0 0 ), no n - 
im m unogenic m olecules w hich can fortunately  be m ade im m unogen ic  by  cova len t
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attach m en t to  la rg er m o lecu les such as p ro te in s. 1 1 5 ,1 1 6  p)ue to  the  lack  o f  
su itab le  functional g roups in the stero id  m o lecu le  itse lf, d e riv a tiv e s  are  req u ired  
w hich  can then  be linked  to  the e-am in o  group  o f  ly s in e  re s id u es  on  th e  p ro te in  
carrier. T he  deriv a tiv e  p rov ides a "bridge" o f  fo u r to  six ca rb o n  a tom s b e tw een  
ca rrie r and  hap ten  w hich  im p ro v es spec ific ity  by a llo w in g  th e  h ap ten  to  p ro jec t 
above the h y d ra ted  su rface  o f  the  p ro te in . T h e  im p o rtan ce  o f  the "b ridge"  in  
re la tio n  to  the p e rfo rm an ce  o f  an tib o d ies  w ith  io d in a ted  s te ro id  lab e ls  w ill be 
d iscu ssed  la ter. S tab le  s te ro id /b o v in e  serum  a lb u m in  c o n ju g a te s  c a p a b le  o f  
eliciting  an tibody form ation  w ere first p rod u ced  by L ieberm an  and 
E rlanger 117,118 an(j jn 1 9 6 9  the first p ractica l stero id  R IA  w as repo rted . 119
T he an tibody  re sp o n se  to  in jected  im m u n o g en  can  be in c reased  by the in c lu sio n  
o f  ad ju v an ts  - the  m o st w id ely  u sed  w as in tro d u ce d  by  F re u n d l^ O  jn 1 9 5 1  ^  
F reund 's  ad ju v an t consists  o f  neu tra l d e terg en t, p a ra ffin  o il and  (in th e  co m p le te  
form ) k illed  m ycobac terium . T he  d e te rg en t b in d s b o th  the o il an d  an  aq u eo u s 
so lu tio n  o f  th e  im m u n o g e n , a llo w in g  th e  fo rm a tio n  o f  a s tab le  e m u ls io n . 
F reund 's  ad ju v an t en ab les  the v ery  slow  re lease  o f  im m u n o g en , av o id in g  ra p id  
up take in to  the circu lation  lead ing  to deg radation  by p ro teo ly tic  enzym es. It a lso  
aids phag o cy to sis  o f  the im m unogen  by  m acro p h ag es, cau ses  the  fo rm a tio n  o f  a 
local g ranu lom atous lesion  w hich  m ay  act as a fo cu s fo r an tib o d y  fo rm a tio n  and  
causes local and general stim ulation o f  the re ticu lo -endo thelial system .
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1.3.2. Characterisation of Antibody
A ntisera  are characterised  by titre and specificity.
Titre
T itre  is the  d ilu tio n  o f  an tise ru m  used  in  the assay  tu b e  to  en su re  a b in d in g  o f  
labelled  antigen o f  fifty  percen t in  the absence o f  un labelled  h o rm one and  is found  
by p erfo rm in g  an an tib o d y  d ilu tio n  cu rve. S te ro id  an tib o d ies  n o rm a lly  h av e  
titres betw een  1/ 1 ,0 0 0  and  1/ 1 0 0 ,0 0 0 .1 2 1
Specificity
B ecause o f  the natu ral occu rrence o f  m any  stero ids w ith  c lo se ly  re la ted  ch em ica l 
structures, there  is a h igh  risk  that an an tibody  p ro d u ced  in re sp o n se  to  a s te ro id  
im m unogen  m ay  no t be abso lu te ly  spec ific  fo r th e  se lec ted  stero id . T h is  m ean s 
th a t assessm en t o f  the  sp ec ific ity  o f  s te ro id  an tise ra  is  m an d a to ry . A n tib o d y  
specificity  can be assessed by cross reaction  studies. A n  index  o f  spec ific ity  can 
be o b ta in ed  fro m  d isp lace m e n t s tu d ies  an d  is c a lc u la te d  fro m  th e  m ass  o f  
im m u n o g en ic  s te ro id  re q u ire d  to  d isp lace  f if ty  p e rc e n t o f  th e  ra d io la b e lle d  
im m unogen ic  stero id  to  the m ass o f  cro ss  reac tin g  s te ro id  to  d isp lace  the  sam e 
p e rcen tag e  o f  lab e lled  stero id . 119 x h is  c ro ss  rea tio n  eq u a tio n  is g iv en  in  the  
equations section.
T h e  sp ec ific ity  o f  a p a rtic u la r  an tise ru m  m ay  b e  s tro n g ly  in f lu e n c e d  b y  the  
p o sitio n  on  the stero id  n ucleus u sed  fo r  co n ju g a tio n . S ev era l w o rk e rs  h av e  
sh o w n , 122,123 fo r exam ple , that an tisera  tend  to  be spec ific  fo r  th a t p a r t o f  the 
steroid m olecule furthest from  the site o f  conjugation . H ence, an an tise ru m  m ay  
be m ore likely to  recogn ise changes in the D  ring  if  the site o f  con jugation  is at the 
3-position .
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1.4. L a b e l
E ssential to any b inding assay is a m eans fo r determ in ing  the d istribu tion  betw een  
the an tib o d y  bound  and free  fractions. T h is  is ach iev ed  by  in co ro p o ra tin g  a 
sm all am o u n t o f  h igh ly  p u rif ied  lab e lled  lig an d  in to  th e  assay  sy s tem  w h ich  
shou ld  b ehave sim ilarly  to  the  u n lab e lled  lig an d  and  be d e tec tab le  by accu ra te , 
d irec t an d  sim p le  p ro c ed u re s . C u rre n tly , ra d io a c tiv e  lab e ls  a re  th e  m o s t 
com m on  type  in  h o rm o n e  assays bu t n o n -iso to p ic  lab e ls  such  as en z y m e s  an d  
lum inescent reagen ts are becom ing increasingly  popular.
G am m a-em itting  iso topes o f  iod ine e .g . 125j can  be u sed  to  label 
stero id s . ^24-127 A lthough  this iso tope has the d isad v an tag e  o f  a re la tiv e ly  short 
h alf-life  (60  days), it has a h igh  spec ific  ac tiv ity  (up to  2 ,2 0 0  C i/m m o l) and  is 
easie r and  cheaper to  de tec t than tritium . F o r 125^ ex p en siv e  sc in tilla tio n  flu id  
is not requ ired  and m ultihead  counters allow  fast sam ple throughput.
T he io d in e  a to m  is co m p arab le  in size to  th e  A  rin g  o f  the s te ro id  n u c leu s  an d  
w o u ld  ca u se  co n s id e rab le  d is to rtio n  o f  the  m o le c u le  i f  it  w as in c o rp o ra te d  
d irec tly . Iod in e  is, th ere fo re , firs t bound  to  an a ro m atic  am in e  w h ich  is th en  
lin k ed  to  an ac tiv a ted  stero id  d eriva tive . D e ta ils  o f  the co n ju g a tio n  lab e llin g  
m eth o d  em p lo y in g  C h lo r a m i n e - T 1 2 8 are  il lu s tra te d  in  F ig . 8 . S o d iu m  
[ 125 i]-iod ide  is in itially  converted  to  a m ore  reactive  fo rm  (free io d in e  o r  1+) by 
the strong oxid ising  agent, C h loram ine-T , w hich  causes a d irec t io d in a tio n  o f  the 
arom atic am ine (ty ram ine o r h istam ine). T he reaction  is stopped  by the  add ition  
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is then  lin k ed  to  the s te ro id  n u cleu s th ro u g h  a m ix ed  an h y d rid e  re a c tio n  to  a 
c a rb o x y m e th y lo x im e  o r h e m isu cc in a te  b r id g e . 1 1 2  T h e  io d in a ted  s te ro id  is 
finally  p u rif ied 1 2 9  before use in R IA  by paper, th in  lay er o r  h igh  p ressu re  liqu id  
chrom atography.
1.5. S e p a r a t i o n  M e t h o d s
O n ce  the  p rim ary  an tib o d y -h a p te n  re ac tio n  is  c o m p le te , it is  n e c e ssa ry  to  
determ ine the d is trib u tio n  o f  the hap ten  b e tw een  th e  b o u n d  an d  the  free  fo rm s. 
U sually , this requires that the bound fraction be physically  separated  from  the free  
frac tio n . A  go o d  sep a ra tio n  m e th o d  sh o u ld  b e  q u ick , e ff ic ie n t, ch e ap  an d  
uncom plicated  to  enable large sam ple capacity  to be achieved.
1.5.1. Dextran-Coated Charcoal
T he use  o f  ad so rp tion  o f  the  u n b o u n d  s te ro id  frac tio n  by  ch a rco a l m o d ified  by  
coa ting  w ith  d ex tran  w as p roposed  in 1 9 6 5 . 130 T h is m eth o d  o f  sep a ra tio n  w as 
used  ex ten siv e ly  in  early  stero id  R IA 's  w ith  ad eq u a te  p rec is io n . T em p e ra tu re  
and  tim e o f  ex p o su re  to  d ex tran  co a ted  ch a rco a l su sp en sio n s, h o w ev er, re q u ire  
c a re fu l o p t im is a t io n  to  a v o id  " s tr ip p in g "  o f  a n t ig e n  f ro m  a n tib o d y . 
"M agnetisab le charcoal" has been  deve loped  in w hich  ch arco a l and  m ag n e tisab le  
ferric ox ide trapped  in a p o lyacry lam ide gel pe rm it separa tion  by  a m ag n e t ra th e r 
than cen trifu g atio n .13 1
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1.5.2. Second Antibody
In 1962, a separation  p ro ced u re  w as in tro d u c e d 132 jn R IA  sy stem s in  w h ich  a 
second antibody  (A b-2) specific to  the y-g lobulin  o f  the spec ies in  w h ich  the first 
an tibody w as ra ised , is used  to p recip ita te  the b ound  com plex . D o u b le  an tibody  
separations are h igh ly  specific  and  are cap ab le  o f  a lm o st co m p le te  sep a ra tio n  o f  
bound  and  free  fo rm s o f  an tigen . O p tim isa tio n  o f  th is  m e th o d  re q u ire s  ca re fu l 
selection  o f  the second  an tibody  co n cen tra tio n  to  allow  to tal p rec ip ita tio n  o f  the 
bound  fraction .
T he m a jo r d isad v an tag es  o f  the  d o u b le  an tib o d y  m e th o d  a re  th e  re a g e n t co s t 
in v o lv ed  in  se lec tin g  an d  su p p ly in g  la rg e  v o lu m e s  o f  a n tis e ru m  (se co n d  
an tibod ies have lo w er affin ities  and  m ust, th ere fo re , be u sed  at lo w er titres), the 
p ro lo n g ed  in cu b a tio n  tim e re q u ired  to  ac h ie v e  c o m p le te  sep a ra tio n  an d  th e  
in te rfe ren ce  th ey  can  su ffe r fro m  a n u m b er o f  n o n -sp e c ific  fac to rs . ^ 3  T he
add ition  o f  a p ro te in  p rec ip itan t such  as p o ly e th y len e  g ly co l can  fa c ilita te  the  
fo rm a tio n  o f  the firs t an tib o d y -sec o n d  an tib o d y  co m p le x  an d  so  re d u c e  th e  
incubation  tim e .134
1.5.3. Solid Phase
In  so lid  p h ase  separa tion  system s, the an tib o d y  (e ith e r firs t o r  seco n d ) can  be 
coup led  to  an inso lub le  support, ^ 5  such as partic les o f  ce llu lo se , d ex tran , la tex  
p o ly m e r, m ic ro n  s ized  g la s s  o r  c o n tin u o u s  s u rfa c e s  o f  p o ly s ty re n e  o r  
p o ly p ro p y len e  d iscs  o r  the w alls  o f  p lastic  tubes. B ecau se  o f  th e  ad so rp tiv e  
p ro p e rtie s  o f  p la s tic  su rfaces , tu b es  an d  d isc s  can  be d ire c tly  c o a te d  w ith  
an tibody . T he  adso rp tive  in terac tio n  is, h o w ev er, less  s tab le  th an  co v a le n t 
linkage, and  h ence the m ajo r d raw b ack  is lack  o f  rep ro d u c ib ility . W h en  the
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an tiseru m  is co v a len tly  lin k ed  to  p articu la te  so lid  p h ase , an y  lo ss  o f  an tib o d y  
affin ity  (and therefo re  assay  sensitiv ity ) due to  co u p lin g  can  be co m p en sa ted  by 
im proved  precision  resu lting  from  the efficiency  o f  s e p a r a t i o n .136
A n a lte rn a tiv e  ap p ro ach  is the u se  o f  an tib o d y  co v a le n tly  b o u n d  to  m ag n e tic  
partic les (polym er-coated  iron oxide), ^ 7  a system  w here m ix in g  and  separation  
are sim ply achieved by the application o f  a m agnetic field.
1.5.4. M icroencapsulated Antibody
A  reag en t idea l fo r use in  hap ten  R IA  is en cap su la ted  an tib o d y . T h e  la rg e  
antibody m olecu le  is su rrounded  by a p o ly am id e  m em b ran e , p e rm eab le  o n ly  to  
sm all m o lecu lar m ass m o lecu les  such  as s te ro id  h o rm o n es. C en trifu g a tio n  o f  
the m icrocapsules con tain ing  an tibody separates the an tibody  bound  from  the free 
fra c tio n . T h is  m e th o d  o f  s e p a ra tio n  s te m m e d  fro m  e a r ly  w o rk  o n  
m i c r o c a p s u l e s ^ 8  an d  a rtific ia l c e l ls 139 co n ta in in g  p ro te in s ,1^  su ch  as 
erythrocyte haem olysates and enzym es.
T he sem i-perm eab le  m em b ran e  iso la tes  and  p ro tec ts  the e n c ap su la ted  p ro te in , 
w hile allow ing  free  transfer o f  low  m olecu lar m ass co m p o u n d s b e tw een  ex tern a l 
and in terna l en v iro n m en ts . H en ce , the su itab ility  o f  m ic ro c ap su les  to  h ap ten  
and free  h o rm one R IA 's. U se  o f  m icro cap su les  in  R IA  has b een  re p o rte d  fo r 
d igox in , 1^ 1 free t h y r o x i n e 142-144  and  cortiso l. ^ 5
T he p rep ara tio n  o f  m icro cap u les  in v o lv es  p o ly m erisa tio n  at th e  in te rfa ce  o f  a 
w a te r-in -o il em u lsio n . T h is is acco m p lish ed  by fo rm in g  an  em u ls io n  o f  an  
a lk a lin e  a q u e o u s  so lu tio n , c o n ta in in g  a d ia m in e  p lu s  th e  p ro te in  to  b e  
encapsu la ted , in an o rgan ic  so lven t system . T h en  a d iac id  ch lo rid e , w h ich  is 
so lub le  on ly  in the o rg an ic  so lven t, is ad d ed  to the  em u ls io n . T h e  d iam in e ,
4 8
w hich  has som e solubility  in the o rgan ic  so lvent, d iffu ses  in to  the  o rg an ic  p h ase  
and  fo rm s a p o ly m er m em b ran e  on the  o rg an ic  so lv en t s ide  o f  the  in te rfa c e  
according to the reaction:
H2-R1-NH2 + C10C-R2-C0C1 — >
[-HN-R l -NH-CO-R2-CO-]n + HC1
T he encap su la ted  d rop lets  are separated  fro m  the  o rg an ic  so lven t, w ash ed  w ith  
detergent and resuspended  in an aqueous m edium .
A  com parison  o f  th ree  sep ara tio n  m eth o d s o f  R IA  fo r  1 7 -h y d ro x p ro g es te ro n e  
using  the sam e an tiserum  m icro en cap su la ted , lin k ed  to  ce llu lo se , o r  in  so lu tio n  
has been carried  ou t. 146 M icroencapsu la ted  an tibody  co m p ared  w ell w ith  so lid  
p h ase  an tib o d y  and  p e rfo rm ed  b e tte r th an  a "so lu b le"  an tib o d y  sy s tem  w ith  
charcoal separation . W ork  has been  a lso  been  ca rried  o u t on  ly o p h y lise d  
c a p s u le s .  147 T he m icrocapsu les con tain ing  an tibody  are su ffic ien tly  ro b u st to 
w ithstand  rep ea t d ispensing  and are o f  s im ilar d en sity  to  the m ed iu m  an d  rem ain  
in suspension  du rin g  incubation . P rep a ra tio n  o f  m ic ro en cap su la ted  an tib o d y  
is quick , cheap  and  rep ro d u cib le  and  w as, co n seq u en tly , u sed  in  th is  stu d y  fo r 
initial cross-reaction  experim ents. C ross-reaction  stud ies w ith  a so lub le  second  
antibody y ielded  sim ilar inform ation.
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1.6. E x t r a c t i o n  V e r s u s  D i r e c t  R IA
In b io lo g ic ia l flu ids, s tero ids m ay  o cc u r in  fo rm s o th e r th an  as free  s te ro ids. 
T hey  can bind  to pro teins o ther than an tib o d ies148  o r  can  be p resen t in  the fo rm  
o f  conjugates. A lbum in  b inds stero ids w eak ly  bu t has a h igh  cap ac ity  fo r them . 
C ertain  steroids b ind  w ith  h igh  affin ity  to  co rtiso l-b in d in g  g lo b u lin  (e.g . co rtiso l 
and  p ro g es te ro n e) and  sex -h o rm o n e-b in d in g  g lo b u lin  (e .g . te s to s te ro n e  an d  
an d ro sten ed io n e).14^ S tero ids a lso  o ccu r as co n ju g a tes  m ain ly  as su lp h ates  o r  
g lu co sid u ro n id a tes . T h e  p re sen ce  o f  th ese  o th e r  fo rm s  o f  s te ro id s  c rea te s
problem s w hen a stero id  is being  m easured  by R IA  in w ho le  b lood .
T he extraction o f  steroids by organic so lvent p rio r to RLA is a  m ean s o f  separating  
th em  fro m  w a te r-so lu b le  s te ro id  co n ju g a te s  an d  se ru m  p ro te in s  an d  th u s  
increases assay specificity . O n the o ther hand , an  ex trac tio n  step is a source  o f  
im precision and error. ^ 0
T he e lim in a tio n  o f  the ex trac tio n  step and  d ev e lo p m en t o f  a d irec t R IA  fo r  th e  
m easu rem en t o f  s te ro id s  o ffe rs  c o n s id e rab le  p o te n tia l ad v a n ta g es , in c lu d in g  
p ractical conven ience, im proved  p recision , av o id an ce  o f  h azard o u s so lv en ts  and  
la rg e r batch  s iz e s .*51 i n 1982, d irec t non  ex trac tio n  R IA 's  fo r p ro g e s te ro n e  
w ere  re p o rted  w h ich  co m p ared  fa v o u rab ly  w ith  th o se  h a v in g  c o n v e n tio n a l 
ex traction  procedures. ^ 2  R IA  inco rp o ra tin g  an ex trac tio n  step  is im p rac tica l 
fo r use in la rg e -sca le  screen ing  b ecau se  o f  the  h ig h  sam p le  th ro u g h -p u t (e .g . 
200-500  sam ples/day  fo r the Scottish  neonata l population).
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C H A P T E R  2 M A T E R IA L S A N D  M E T H O D S
A P P A R A T U S
G am m a ra d ia tio n  w as  m easu red  on a N E -1 6 0 0  G a m m a  C o u n te r , N u c le a r  
E n te rp rise s , E d in b u rg h , U .K . an d  b e ta  ra d ia tio n  w ith  a  "P rias"  sc in tilla tio n  
co u n te r from  C an b erra  P ack ard , P an g b o u m e, B erk sh ire , U .K . P u rifica tio n  o f  
rad ioactive  labels  in v o lv ed  the  use o f  T .L .C . p la tes (p re-coa ted  w ith  silica  gel 60 
F 2 5 4 ) fro m  M erck  C lin ica l R esea rch  D iv is io n , 267  C h u rch  S t., B lack p o o l,
L ancash ire , U .K ., w h ich  w ere  scanned  on a R ad io ch ro m a to g ram  S can n e r fro m  
P ack a rd  In s tru m e n ts  L td ., 13-17 C h u rch  R d ., C av e rsh a m , B e rk sh ire , U .K . 
S o lv en t ex tra c tio n  o f  s te ro id s in v o lv ed  the use  o f  a Z ip p e tte  R ep ea tin g  P ip e tte  
from  Jen c o n s  S c ien tific  L td ., C h erry  C o u rt In d u stria l E s ta te , S ta n b rid g e  R d ., 
L e ig h to n  B u z z a rd , U .K ., an  S .M .I. M u lt i-T u b e  V o r te x e r  f ro m  A lp h a  
L ab o ra to rie s , E as te ig h , H am p sh ire , U .K . an d  a B u ch le r V o rtex  E v a p o ra to r  
from  A rn o ld  H o rw ell, L o n d o n , U .K . Im m u n o g en  w as d isso lv e d  w ith  the  a id  
o f  a so n ica tin g  w a te r b a th  fro m  Q .H . K erry , K erry  U ltra so n ic s  L td ., H u n tin g  
G a te , W ilk b u ry  W a y , H itc h in , H e r tfo rd s h ire ,  U .K . o r  an  U ltra s o n ic  
D is in tig ra to r P ro b e  fro m  M .S .E . S c ien tific  In s tru m en ts , M a n o r R d ., C raw ley , 
W est S ussex , U .K . A n  U ltra -T u rrax  D isp e rse r w as o b ta in ed  fro m  Jan k e  and  
K u n g e l, W ro c la w , P o la n d . U .K . a g e n ts :-  S e m a t L td . ,  S t. A lb a n s ,  
H ertfo rdsh ire , U .K . and  w as em ployed  in  the  m icro en cap su la tio n  o f  an tibody .
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U n less  o th e rw is e  s ta te d , c e n tr ifu g a tio n  w as  c a r r ie d  o u t u s in g  a M .S .E . 
"C oolspin" cen trifu g e  (as above). In addition , an u ltracen trifuge  an d  "C entaur" 
ce n trifu g e , b o th  M .S .E . (as ab o v e ) w ere  em p lo y ed . In  th e  p re p a ra tio n  o f
c h a rco a l-s tr ip p ed  serum , W h a tm an  N o .l  filte r p ap e r w as u sed  fro m  W h a tm an  
L ab . S a les  L td ., U n it 1, C a ld red  R d ., P a rk w o o d  In d u s tr ia l E s ta te ,
M aid sto n e , K en t, U .K . G lass  tes t tubes, 10 m l (1 0 0 x 1 6  m m ) an d  
5m l (75x12  m m ), w ere  fro m  S. M u rray  and  C o., H o lb u m  H o u se , O ld  W o k in g , 
S u rrey , U .K . R ep ea t d isp en s in g  o f  reag en ts  w as p e rfo rm ed  w ith  a 200  \xl 
a d ju s ta b le  M ic ro d is p e n s e r  P ip e tte  fro m  S o c o re x , IS B A  L td ., R e m ie n s , 
S w itzerland . P la s tic  tes t tubes, 5 m l (p lastic , 7 5 x 1 2  m m ), w ere  fro m  S arsted t 
L td ., B eau m o n t L ey s, L e iscester, U .K .
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M A T E R IA L S
A ll com m on  reag en ts  an d  so lven ts  w ere  o f  'A nalaR ' g rade and  w ere  fro m  e ith e r 
B .D .H . C h em ica ls  L td . o r  S igm a C h em ica l C o. bo th  D o rse t, U .K . S te ro id s 
w ere  p u rc h a s e d  f ro m  S te ra lo id s  L td ., 31 R a d c lif fe  R d ., C ro y d o n , U .K . 
F reu n d 's  c o m p le te  ad ju v an t w as fro m  D ifc o  L ab o ra to rie s , P .O . B o x  1058 A , 
D e tro it, M ich ig an , U .S .A . P rec ip ita tin g  an tib o d y  (d o n k ey  an ti-ra b b it an d  
donkey  an ti-sh eep ) w as supp lied  by  the S co ttish  A n tib o d y  P ro d u ctio n  U n it, L aw  
H o sp ita l, C arlu k e , U .K . A n tise ra  w ere  ra ised  in  N ew  Z ea lan d  w h ite  rab b its . 
T ritia ted  an d ro s ten ed io n e  ([1 ,2  6 ,7 -^ H ]-an d ro s t-4 -en e -3 ,1 7 -d io n e ) an d  N a ^ I  
w ere  su p p lied  fro m  A m ersh am  In te rn a tio n a l, B u ck in g h am sh ire , U .K . T h e  
an tise ru m  u sed  w ith  th e  trit ia te d  tra c e r  w as su p p lied  by G u ild h ay  A n tise ra , 
U n iv e rs ity  o f  S u rre y , U .K ., an d  w as ra is e d  a g a in s t a n d ro s te n e d io n e -1 7 a -  
c a rb o x y th io -e th e r  o v a lb u m in  (ref. no . H P /S /6 7 3 -1  A ). H e x a n e -1 ,6 -d ia m in e , 
te reph thaloy l ch lo rid e  and  Span  85 (so rb itan  trio leate) w ere  o b ta in ed  from  K och- 
L igh t L ab o ra to ries , S lough , B erksh ire , U .K . T he fo llo w in g  reag en ts  w ere  from  
S ig m a  (as a b o v e ): T w e e n  2 0  (p o ly o x y e th y le n e  s o rb ita n  m o n o la u ra te ) ,
iso b u ty lch lo ro fo rm ate , N -(2 -h y d ro x y e th y l)-p ip e raz in e -N l-3 -p ro p an e su lp h o n ic  
ac id  (E P P S ), b o v in e  se ru m  a lb u m in  (f rac tio n  V ) a n d  c a rb o d iim a d a z o le . 
Sepharose-C 14B  w as o b ta in ed  from  P h arm ac ia  F in e  C h em ica ls , A  B , B o x  175, 
45-751 04  U p sala , S w eden . T ri-N -b u ty lam in e  w as fro m  E astm an -K o d ak  C o., 
R ochester, N ew  Y ork , U .S .A . an d  abso lu te  a lcoho l w as fro m  Jam es B u rro u g h s 
L td ., 60  M o n tfo rd  PI., L o n d o n ,U .K . N ew ly - ex p ired  p ac k s  o f  e ry th ro cy te s
w ere  o b ta in e d  fro m  B lo o d  T ra n s fu s io n , S to b h ill H o sp ita l,  G la sg o w , U .K . 
F ilte r p ap e r ca rd s  (S ch le ise r and  S chuell, g rade  2 9 9 2  ce llu lo se ) fo r b lo o d  spots 
w ere o b ta in ed  fro m  A n d erm an  &  C o., 145 L ondon  R d., K in g sto n -u p o n -T h am es, 
S urrey , U .K . D io x an  w as p u rified  befo re  use  by  ru n n in g  it th ro u g h  a g lass 
colum n packed  w ith chrom atograph ic standard  alum ina.
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2.1. P r e p a r a t i o n  o f  S o l u t i o n s  a n d  B u f f e r s
Phosphate B u ffer  (0 .05 M , p H  7.4)
U n less  o th e rw ise  s ta ted , a p h o sp h a te  b u ffe r  (0 .5  mol/1 p H 7 .4 ) w as u sed  an d  
w as p re p a re d  as fo llo w s: A  0 .2 5  M  so d iu m  d ih y d ro g en  o r th o p h o sp h a te
so lu tion  (A) w as p rep ared  by d isso lv in g  70 .98  g N aH 2 P O 4 .2 H 2 0  in d is tilled
w ater and  m ak in g  up  to 250  m l. A  0.5 M  d isod ium  hydrogen  o rth o p h o sp h ate  
so lu tion  (B ) w as p rep ared  by  d isso lv ing  35.5 g N a2 H P 0 4  in  d is tilled  w a te r and
m ak ing  up  to  500  m l. S o d iu m  ch lo rid e  (17.5  g) an d  m erth io la te  (0 .5  g) w ere  
d isso lv ed  in  d is tilled  w a te r (250  m l). S o lu tion  A  (30  m l) an d  so lu tio n  B (120  
m l) w ere  ad d ed  to  th is and  m ixed . T h e  p H  w as ch eck ed  an d  ad ju s ted  to  7 .4  
and the so lu tion  d ilu ted  to  2 1 w ith d is tilled  w ater. T h e  so lu tion  w as sto red  at 
4  ° C  fo r up  to  6  m onths.
RIA B u ffer
R IA  b u ffe r w as fresh ly  p rep ared  fo r each  assay  by  d isso lv in g  B S A  (0 .25%  w /v) 
in p h o sp h ate  buffer.
Citrate B uffer  (N a C itrate/H C l, pH  4.0)
A  d iso d iu m  c itra te  so lu tion  w as p rep ared  by d isso lv in g  c itric  ac id  m o n o h y d ra te  
(21.01 g) in  a v o lu m e o f  d istilled  w ater (500  m l). S od ium  h y d ro x id e  (200  m l o f  
a 1M  so lu tio n ) w as ad d ed  an d  the so lu tio n  w as m ad e  up  to  1 1 w ith  d is til le d  
w ater. H y d ro ch lo ric  ac id  (8.77 m l o f  0.1 M ) w as d ilu ted  to  1 1 w ith  d is tilled  
w ater. C itra te  b u ffe r (pH  4 .0) w as p repared  by m ix in g  d iso d iu m  c itra te  so lu tion  
(55.1 m l) w ith  h y d ro ch lo ric  acid  (44 .9  m l o f  0 .1M ).
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EPPS C oupling B uffer  (E PPS 0.1 M , N a az ide  0 .05%  w /v , p H  8.0)
E PPS (25 .23  g) w as d isso lv ed  in  d is tilled  w a te r (750  m l) and  titra ted  to  p H  8.0 
w ith sod ium  h y d ro x id e  (1 .0  M ). S od ium  az ide (500  m g) w as d isso lv ed  in  th is 
so lu tion  and  the  v o lu m e m ad e  up to  1 1 w ith  d is tilled  w ater. E P P S  b u ffe r w as 
stored at 4  ° C  fo r up  to one m onth .
Bicarbonate Solution  (0.5 M , pH  8.0)
Sodium  b icarbonate  (42 g) w as d isso lved  in d istilled  w ater and  m ade up to  11. 
A cetate B u ffer  (0.1 M , p H  4.0)
A n h y d ro u s  so d iu m  ace ta te  (1 .74  g) w as d isso lv ed  in  d is tilled  w a te r  (7 5 0  m l). 
G lacia l acetic ac id  (9 m l) w as added  and the vo lum e m ade up to  11 w ith  d istilled  
w ater.
Isotonic Saline  (0 .154  M )
Sodium  ch lo ride  (9 g) w as d isso lved  in d istilled  w ater and m ade up to  1 1.
W ash Solution  (0 .9%  N a /C l w /v , 0 .2%  T w een  20 v /v)
A  so lu tion  o f  iso to n ic  sa line  w as p rep ared  (5 1) to  w h ich  T w een  20  (10 m l) w as 
added  an d  m ix ed  b efo re  s to rin g  at 4  ° C . T h e  su p e rn a tan t w as re m o v e d  an d  
d iscarded by a m ulti-head  asp ira to r linked  to  a vacuum  pum p.
Organic Phase
C hloroform /cyclohexane (1:4,v /v) con ta in ing  1% sorb itan  trio leate.
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Diamine Reagent
S o d iu m  b ica rb o n a te  (0 .8  g) and  h ex an e-1 ,6 -d iam in e  (1 g) w ere  d isso lv ed  in  
10 m l d is tilled  w a te r and  the pH  ad ju sted  to  9 w ith  5 mol/1 h y d ro ch lo ric  acid . 
P o ly e th y len e im in e  (2 g o f  a 50%  solu tion) w as added , m ix ed  fo r 10 m in  and  the 
final v o lum e adjusted  to 2 0  m l w ith d istilled  w ater.
Organic D iacid Chloride Reagent
P ow dered  tereph thaloy l ch lo ride  (1 g) w as added  to  180 m l o f  o rgan ic  p hase  and 
m ix ed  a t 4  ° C  fo r  1 h. U n d isso lv ed  te re p th a lo y l ch lo rid e  w as re m o v e d  by  
cen trifugation.
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2.2. P r e p a r a t i o n  o f  S t a n d a r d  M a t e r i a l  f o r  R IA
2.2.1. Androstenedione Standard Solutions for RIA Development
A n d ro s te n e d io n e  (1 m g ) w as d is so lv e d  in e th a n o l (1 0  m l), g iv in g  a s to ck  
standard  so lu tion  o f  100 |ig /m l. T h e  stock  standard  so lu tion  (1 m l) w as d ilu ted  
w ith  e th an o l (99 m l), g iv ing  an in te rm ed ia te  so lu tion  o f  lp g /m l. In te rm ed ia te  
so lu tion  (500  (il) w as ev ap o ra ted  to  d ryness in a 100 m l v o lu m etric  flask . R IA  
b u ffe r ( 1 0 0  m l) w as ad d ed  to  the d ried  re s id u e  to  g ive  a  w o rk in g  so lu tio n  o f
5 ,0 0 0  p g /m l. W o rk in g  s ta n d a rd s  w e re  p re p a re d , as sh o w n  in  T a b le  3. 
A liq u o ts  (2 0 0  p i)  o f  each  s tan d ard  so lu tio n  w ere  p ip e tted  in to  ap p ro p ria te ly  
labelled  p lastic  tes t tubes (5 m l, 75x12  m m ), sealed  and  sto red  at -20  ° C  fo r up 
to  6  m on ths.
2.2.2. Steroid Standard Solutions for Cross Reaction Studies
S tero id  (1 m g) w as d isso lv ed  in  e th an o l (1 0  m l), g iv in g  a s to ck  s tan d a rd  
solution  o f  100 p g /m l, w h ich  w as stored  at 4  °C . S tock  standard  so lu tion  (1 m l) 
w as d ilu te d  w ith  e th an o l (9 9  m l) g iv in g  an in te rm ed ia te  so lu tio n  o f  1 p g /m l 
w hich  w as a lso  sto red  at 4  °C . In term ed ia te  so lu tion  (1 m l) w as ev ap o ra ted  to  
d ryness u n d er a s tream  o f  air. R IA  b u ffe r (6.7 m l) w as added  and  w ell m ixed , 
g iv ing  a w o rk in g  so lu tio n  o f  30 ,000  p g /2 0 0  p i, w h ich  w as fresh ly  p re p a re d  fo r 
each R IA .
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Table 3. Serial dilutions of the working solution (5,000 pg/ml) of
androstenedione (A4) used to prepare standards.
V o l u m e  (m l )
W o rk in g  C o n c e n t ra t io n
S ta n d a r d  S o lu t i o n  R IA  B u f fe r  A 4  (p g /2 0 0  p i )
0 0 . 0 1 0 . 0 0 .0
1 0 .1 9 . 9 10
2 0 . 2 9 . 8 20
3 0 . 5 9 . 5 50
4 1.0 9 . 0 100
5 2 . 0 8 . 0 2 0 0
6 4 . 0 6 . 0 4 0 0
7 8 . 0 2 . 0 80 0
2.2.3. Androstenedione Standard Solutions for Serum RIA
A n d ro sten ed io n e  standards w ere  p rep ared  by  d isso lv in g  A 4  in  e th an o l to  g ive  a 
final co n cen tra tio n  o f  100 mg/1. T h is so lu tion  w as fu rth e r d ilu ted  in  e th an o l to  
g ive co n cen tra tio n s  o f  0 .7 , 1.4, 3 .5 , 7 .0 , 10.5, 17.5, and  21 nmol/1.
2.2.4. Androstenedione Blood Spot Standards
A  su itab le  m a te r ia l w as p ro v id ed  by the  add ition  o f  ch a rco a l-s tr ip p e d  seru m  to 
sa line-w ashed , p ack ed  ery th rocy tes. T h is  w as then sp iked  w ith  an d ro sten ed io n e  
and spotted  o n to  filte r p ap e r cards.
A ) P rep a ra tio n  o f  ag a ro se-co a ted  ch arco a l: A g aro se  (12 .5  g) w as ad d ed  to  
d istilled  w a te r  (250  m l) and  h ea ted  to  70  ° C  w ith  co n stan t stirring . A c tiv a ted  
charcoal (50  g) w as then  added  and  m ix ed  to  fo rm  a th ick  slurry . T h is  w as 
a llow ed  to  coo l to  ab o u t 50 ° C  befo re  add ing  to  acetone (500  m l) w ith  v ig o ro u s 
stirring  in  a F u m e cupboard . A  g ran u la r p rec ip ita te  o f  ag a ro se-co a ted  ch a rco a l 
w as sep a ra ted  by  f iltra tio n  th ro u g h  W h a tm an  N o .l  f il te r  p ap e r. T h is  w as 
spread o n  filte r paper, covered  and  left overn igh t to  dry.
B) P rep a ra tio n  o f  ch a rco a l-s tr ip p ed  serum : A g a ro se -co a ted  ch a rco a l (10  g)
w as ad d e d  to  p o o le d  fem a le  seru m  ( 1 0 0  m l) an d  p la c e d  on  a ro ta ry  m ix e r 
o vern igh t a t ro o m  tem peratu re . T he m ix tu re  w as cen trifu g ed  at 3 ,000  rp m  fo r 
15 m in u tes  in  p o ly p ro p y len e  cen trifu g e  tubes (2x50  m l). T h e  su p e rn a tan t w as 
d ecan ted  in to  tu b es  an d  fu rth e r sed im en ted  in  an u ltracen trifu g e  at 1 0 ,0 0 0  rp m  
fo r 30 m in.
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C ) C o n stru c tio n  o f  w h o le  b lood  m atrix : N ew ly -ex p ired  p ack ed  e ry th ro cy tes  
(40 m l) w ere  added  to  g raduated  po ly p ro p y len e  cen trifu g e  tubes (4x50  m l) and  
spun  a t 3 ,0 0 0  rp m  fo r  20  m in . T h e  top lay e r o f  seru m  and e ry th ro cy tes  w as 
asp ira ted  leav in g  25 m l p ack ed  ery th rocy tes. Iso ton ic  saline (25 m l) w as added , 
w ell m ixed  and cen trifuged  as above. T h e  supernatan t w as asp ira ted , d iscarded  
and  the p ack ed  ery th ro cy tes  rew ash ed  w ith  saline. T he  superna tan t and  the  top 
lay er o f  pack ed  ery th rocy tes w ere asp ira ted  leav ing  15 m l o f  p acked  ery th rocy tes 
in  each  ce n tr ifu g e  tube. T h e  p ack ed , e ry th ro cy te  a liq u o ts  w ere  p o o led  and  
m ixed . C h arco a l-s trip p ed  serum  (50 m l) w as added  to  an  eq u iv a len t v o lu m e o f  
sa line-w ashed  packed  ery th rocy tes and  w as w ell m ixed  to  p roduce  a w hole  b lood  
m atrix  fo r the construc tion  o f  androstened ione d ried  b lood  spot standards.
D ) C o n stru c tio n  o f  d ried  b lo o d  spo t standards: In te rm ed ia te  an d ro s ten ed io n e  
standard  so lu tion  (300  p.1 o f  1 p.g/ml) w as evaporated  to d ryness in  each  o f  tw o  
sm all co n ica l flasks. F o r the top standard , I, 4 .5  m l o f  b lo o d  w as ad d ed  
to  o n e  f la sk  (g iv in g  525 nm ol/1 an d ro s te n ed io n e  in  serum , a ssu m in g  a 50%  
haem atocrit). T o  the o th er flask  w as added  6  m l o f  b lood  (g iv ing
350 nm ol/1 an d ro s ten ed io n e  in  serum ). A fte r 10 m in , bo th  flask s  w ere
w ell m ix ed  an d  th e  co n ten ts  o f  the  la tte r  (s tan d ard  H ) w as d o u b le  d ilu te d  w ith  
b lood , as sh o w n  in  T ab le  4, to g ive  a standard  curve.
F ilte r p ap e r ca rd s  w ere  labe lled  w ith iden tifca tion  fo r each  standard  and  arranged  
h o rizo n ta lly , ra ise d  up o f f  the bench . A fte r m ix in g , a liq u o ts  (25 p.1) o f  each  
s tandard  w ere  spo tted  o n to  the ca rd s w h ich  w ere k ep t fla t fo r  a m in im u m  o f  
15 m in. T he  ca rd s  w ere  a llow ed  to  d ry  at room  tem pera tu re  fo r at least 6  h and  
stored in an a ir-tigh t co n ta in e r at 4  ° C  fo r up to  8 w eeks.
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Table 4 . Serial dilutions of androstenedione (A4) in blood used 
to prepare blood-spot standards. The resulting A4 concentration"1" 
in a blood-spot disc is given.
S tand ard A 4 (nmol/1 serum ) A 4 (p g /5  m m  d isc)
A* 0 0
B 5.5 4 .5
C 1 1 .0 9 .0
D 2 2 .0 18.75
E 43 .7 37 .5
F 87.5 7 5 .0
G 175.0 150.0
H 350 .0 3 0 0 .0
I 5 2 5 .0 4 5 0 .0
(+) G iven  that a 5 m m  blood spot disc con tains 6  p i o f  w hole b lood (or 3 p i o f  
serum ).
(*) B lood  (3 mJ) contain ing  no A4  w as used as the zero  standard  w hich gives 
m ax im u m  binding  o f labelled A4  by antibodies.
2.3. P r o d u c t i o n  o f  R e a g e n t s  f o r  R IA
2.3.1. Production of Androstenedione Antiserum
A n tib o d ies  w ere  ra ise d  ag a in s t th e  im m unogens. A 4 - 3 C M O -B S A , A 4-6(3H S- 
B SA  an d  A 4 - l l a H S - B S A  in rab b its  A /B /C ; D /E /F  an d  G /H /I/J  re sp ec tiv e ly . 
R ab b it G  (fo r th e  A 4 - I  la H S -B S A  im m u n o g en ) d ied  14 d ay s a f te r  th e  f irs t  
im m u n isa tio n , and  w as rep laced  by rab b it J. R ab b its  E  and  I d ied  a fte r 7 and  9 
m o n th s  re sp ec tiv e ly . In  all o th e r cases, the rab b its  su rv ived  fo r m o re  th an  o n e  
year. T h e  im m unisa tion  schedule is ou tlined  in  F ig .9 .
T he p ro ced u re  invo lves th ree stages :
A ) Im m u n o g en  p rep a ra tio n : Im m u n o g en  (1 m g) w as d isso lv e d  in  iso to n ic
saline (4 m l) by  gentle  sonication  in  a sonicating  w ater bath  fo r 3 m in. A n  equal 
v o lum e o f  F reu n d 's  co m p le te  ad ju v an t w as added  and  the tube  p laced  in a b eak er 
o f  cru sh ed  ice. M ore severe sonication con tinued  w ith an  u ltrason ic  d is in teg ra to r 
p robe (se t at freq u en cy  15 kH z) until an em ulsion  w as p roduced .
B) In je c tio n  p ro c e d u re : T h e  im m u n o g e n /F re u n d ’s e m u ls io n  w as  in je c te d  
in tram uscu larly  in to  each o f  3 rab b its  as follow s:
(i) left th igh  - 1 x 0 .5  m l in jection
(ii) rig h t th igh  - 1 x 0.5 m l in jection
(iii) left side o f  sp ine - 2 x 0 .25 m l in jection
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T his p rocedure  w as repeated  at approx im ately  m onth ly  in terva ls fo r 1 year.
C) B leed in g  p rocedure : T en  d ay s  a fte r the th ird  and  su b seq u en t b o osts , a
tes t b leed  (1 m l b lood) w as tak en  from  an ea r vein . T h e  sam ple w as a llow ed  to 
c lo t o v e rn ig h t and  the  serum  sto red  a t -20  ° C  in  100 |i l  a liquo ts . I f  the test 
b leed  o b ta in ed  a h igh  titre  an tib o d y , a la rg e r b leed  (4 0 -5 0  m l b lo o d ) w as 
co llec ted  fro m  an ea r vein . T he  serum  (1 m l) fro m  th is b leed  w as sto red  as 
ab o v e  and  the  rem a in in g  serum  w as d ilu ted  1:1  (v /v) w ith  p h o sp h a te  b u ffe r an d  
sto red  a t -20  ° C  in  20  m l aliquots.
2.3.2. Preparation of Solid Phase Second Antibody
A ll ra b b it an tise ra  w ere  assessed  by titra tio n  stu d ies u sin g  a so lid  p h ase  second  
an tibody  (A b-2) separation  m ethod. D o n k ey  an ti-rabb it an tiserum  w as linked  to 
S epharose  beads to  p ro v id e  th is reagen t.
T he  fo llo w in g  solu tions w ere  fresh ly  prepared :
E P PS  C o u p lin g  B u ffe r (E PPS 0.1 M , N a az ide  0 .05%  w /v , p H  8.0). 
B icarb o n a te  S o lu tion  (0.5 M , p H  8.0)
A ce ta te  B u ffe r (0.1 M , p H  4.0).
Iso ton ic  S aline (0 .154  M )
A ) A c tiv a tio n  o f  S ep h aro se : S ep h aro se -C L -4 B  sto ck  s lu rry  (5 0 0  m l) w as
p o u red  in to  a m easu rin g  cy lin d er and  a llow ed  to  settle  overn ight. Iso ton ic saline 
w as then  ad d ed  to  d o u b le  the  se ttled  gel v o lu m e  g iv in g  a c a lib ra ted  S ep h aro se- 
C L -4B  so lu tion . T h is S epharose-C L -4B  so lu tion  (200  m l) w as added  to  a
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s in te red  g la ss  fu n n e l (p o ro sity  3) w h ich  w as lin k ed  to  a B u ch n e r f la sk  (2 1 
capacity ) and  filter-pum p. T he gel w as dehydrated  by w ash ing  successively  w ith 
500  m l of: (a) d is tilled  w a te r (b) acetone in  d is tilled  w a te r 30%  v /v  (c) acetone 
50%  v /v  (d) ace to n e  70%  v /v  (e) acetone 100%  w ith o u t a llo w in g  the gel to  d ry  
out. T h e  v acu u m  filtra tio n  w as sw itch ed  o ff  b e tw een  w ash es  and  th e  gel w as 
re su sp e n d e d  by g en tly  s tirrin g  w h ile  ad d in g  th e  fre sh  w ash  so lu tio n s . T h e  
d eh y d ra ted  gel slurry  w as fu rth e r re su sp en d ed  in acetone and  transferred  to  a p re ­
c a lib ra te d  co n ica l fla sk  (2 0 0  m l). T h e  v o lu m e  w as m ad e  up to  the 2 0 0  m l 
c a lib ra tio n  m ark  w ith  ace to n e . C arb o n y ld iim id a zo le  (4 .87  g) w as ad d e d  to  
ac tiva te  the  S epharose, the flask  sealed  w ith a g round  g lass s topper and stirred  on 
a m agnetic  s tirrer fo r 60  m in. T he activated  gel w as transferred  to  the  sin tered  
g lass fu n n e l. T he  fla sk  w as rin sed  w ith  ace to n e  w h ich  w as a lso  ad d ed  to  the 
s in te red  g lass  fu n n e l. T h e  gel w as reh y d ra ted  by w ash in g  su ccess iv e ly  w ith  
50 0  m l of: (a) ace to n e  100%  (b) ace to n e  70%  v /v  (c) ace to n e  50%  v /v  (d) 
ace to n e  30%  v /v  (e) d is tilled  w a te r  (f) E P PS  co u p lin g  b u ffe r aga in , w ith o u t 
a llow ing  the gel to  d ry  ou t and  re suspend ing  gen tly  betw een  w ashes.
B ) C o u p lin g  o f  an tib o d y  to  S epharose: D o n k ey  an ti-rab b it an tib o d y  (25 m l) 
w as added  to  a 250  m l p o ly carb o n ate  cen trifuge tube (p re-ca lib ra ted  a t 20 0  m l). 
T he ac tiv a ted  gel w as tran sferred  to the p o ly carb o n a te  bo ttle , m ad e  up to  the 
200  m l ca lib ra tion  m ark  w ith  EPPS coup ling  b u ffer and shaken  gently  overn igh t. 
T h is  w as cen trifu g ed  at 1200 g fo r 20  m in. T h e  p rec ip ita te  w as re su sp e n d ed  by 
the add ition  o f  b icarbonate solution to the calibration  m ark  and shaken fo r 2 0  m in. 
T h is  w as re c e n tr ifu g e d , the  su p e rn a tan t d isca rd ed  and  th e  b ic a rb o n a te  w ash  
rep eated . T h e  p rec ip ita te  w as then  resu sp en d ed  in aceta te  b u ffe r (0.1 M , pH  4), 
m ad e  up to  the  ca lib ra tio n  m ark  and  shaken  fo r 60  m in , re cen trifu g ed , th en  the  
supernatan t d iscarded  and the acetate w ash  repeated  b u t w ith  o v ern igh t shaking.
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T h is  w a s  a g a in  re c e n tr ifu g e d , th e  s u p e rn a ta n t d is c a rd e d , th e  p re c ip i ta te  
re s u sp e n d e d  up  to  2 0 0  m l w ith  iso to n ic  s a lin e  an d  sh ak e n  fo r  2 0  m in . 
R ecen trifu g a tio n  and  the sa line  w ash  w ere  rep ea ted . F in a l cen trifu g a tio n  w as 
fo llow ed  by  re suspend ing  the p recip ita te  in  iso ton ic saline up  to  the ca lib ra tion  
m ark  and  storing  a t 4  °C .
C ) W o rk in g  so lu tio n  fo r  R IA : T h e  sto ck  so lu tio n  o f  so lid  p h ase  seco n d
an tibody , A b-2 , w as d ilu ted  w ith R IA  bu ffer to g ive a 1 % w o rk in g  so lu tion .
2.3.3. Preparation of M icroencapsulated Antibody
T h e m eth o d  w as based  on that o f  W allace  and  W ood. 146
A n  an tib o d y  so lu tion  w as p repared  by add ing  androstened ione an tiserum  (200 |il)  
to  1.8 m l 1% w /v  B S A  an d  C o o m ass ie  b r illia n t b lu e  (10  m g). C o o m ass ie  
b rillian t b lue  is a p ro te in  dye, enab ling  detec tion  o f  any  an tibody  w hich  m ay  have 
leak ed  fro m  the  m icro cap su les . T h e  fo llo w in g  reag en ts  w ere  fresh ly  p rep a red  
and stored  in ice:
O rgan ic P hase
D iam ine R eagent
O rganic D iac id  C hloride R eagent
O rg an ic  p h ase  (30  m l) w as added  to  a 100 m l co n ica l fla sk  o n  ice  an d  m ix ed  
w ith  an U ltra -T u rrax  D isp e rse r op era ted  w ith  an 18N  sta in less steel shaft an d  an 
I.K .I. T h y ris to r speed  co n tro lle r set at 11/2. (T he U ltra -T u rrax  D isp erse r
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h ead  had  been  p re -co o led  in  1 0 0  m l co n ica l fla sk  co n ta in in g  o rg an ic  p h ase  on 
ice). D iam in e  reag en t (3 m l) w as added to  the an tibody  solu tion  and the m ix tu re  
im m ed ia te ly  ad d ed  to  the  m ix in g  o rgan ic  phase . E m u lsif ica tio n  p ro ceed ed  fo r 
90  s an d  in te rfa c ia l p o ly m erisa tio n  w as in itia te d  by  the d ro p -w ise  ad d itio n  o f  
d iac id  ch lo rid e  reag en t (30  m l) added  o v er 1 m in. T h e  m ix in g  co n tin u ed  fo r a 
fu r th e r 2 m in . M ix in g  w as s topped  and  the reac tio n  te rm in a ted  by ad d in g  the  
flask  con ten ts  to  a beaker con tain ing  o rgan ic  phase  (50 m l).
A t th is  s tag e , it  is  n ec e ssa ry  to  tra n s fe r  th e  m ic ro c a p su le s  to  an  aq u eo u s  
en v iro n m en t. T he  cap su les  w ere  firs t sed im en ted  by  ce n trifu g in g  (5 00xg  fo r 5 
m in ) in  2 x 6 0  m l p o ly p ro p y len e  ce n tr ifu g e  tubes. T h e  o rg a n ic  p h a se  w as 
c a re fu lly  d e c a n te d  an d  d isc a rd e d  an d  th e  m ic ro c a p su le  p re c ip ita te  g e n tly  
susp en d ed  in a 40%  v /v  aqueous e thano l co n ta in in g  10% v /v  T w een  20  (10 
m l p e r cen trifu g e  tube). T he final vo lu m e w as in creased  to  50 m l p e r tube  w ith  
40%  v /v  aq u e o u s  e th an o l an d  c e n tr ifu g e d  a t 2 ,0 0 0  x g fo r  30  m in . T h e  
re su ltin g  p e lle t w as w ash ed  several tim es to a to tal v o lu m e o f  4  1 w ith  0 .9%  w /v  
saline and  finally  suspended  in  pho sp h ate  bu ffer (20 m l) and  stored  at 4  °C .
W o rk in g  so lu tion  fo r R IA : T he  req u ired  v o lu m e o f  stock  so lu tion  w as rem o v ed  
an d  R IA  b u ffe r ad d ed  to  g ive  the w o rk in g  d ilu tio n  (i.e. th a t w h ich  g av e  B /T  o f  
40%  in  m icroencapsu la ted  A b d ilu tion  experim ents).
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2.3.4. Preparation of Androstenedione- l ^ I o d o h i s t a m i n e  Labels
T h ree  an d ro sten ed io n e  tracers  w ere  p rep ared  by co u p lin g  each  an d ro s ten ed io n e  
d eriv a tiv e  (A 4 -3 C M O , A 4 -6 PH S and  A 4 -I  l a H S )  to  h is tam in e  w h ich  had  firstly  
been  rad io labelled  w ith  sodium  iodine.
A ) P reparation  o f  androstenedione derivatives: E ach  androstened ione deriva tive  
(2.7 m g) w as p laced  in  a g lass tu b e  (5 m l, 75 x 1 2  m m ) an d  d isso lv ed  in 
d io x an  (500  (il). A 4 -3 C M O  did  no t d isso lv e  easily  and  an ad d itio n a l 500  (il 
w a s  re q u ir e d ,  f o l lo w e d  b y  s o n ic a t io n  in  a w a te r  b a th . T h e s e  
and rosten ed io n e/d io x an  solu tions w ere stored  at -20  ° C  in  50  |i l  a liquots.
B ) A c tiv a tio n  o f  androstened ione: T ri-N -bu ty lam ine /d ioxan  (10 (il o f  1:50 v /v) 
w a s  a d d e d  to  an  a l iq u o t  o f  a n d ro s te n e d io n e  d e r iv a t iv e ,  fo l lo w e d  by  
iso b u ty lc h lo ro fo rm a te / d ioxan  (1 0  (il o f  1 :1 0 0  v /v ), m ix in g  a fte r each  add ition . 
T h is  w as in cu b a te d  fo r 1 h a t 10 ° C  an d  the  reac tio n  th en  q u en c h ed  by  the  
add ition  o f  p re -co o led  d ioxan  (280 (il).
C) Iod ina tion  o f  h istam ine: T he fo llow ing  reagen ts w ere added  to  a 10 m l glass 
tube  (1 0 0 x 1 6  m m ): h istam in e /p h o sp h a te  b u ffe r 0 .5  M , p H  8 .0  (10  (il o f
1.1 m g /5  m l); s o d iu m ! 2 5  iod ide (1 m C i in 10 (il); ch lo ram in e -T /d istilled  w a te r 
(10  (il o f  15 m g /m l). T h e  tube  co n ten ts  w ere  m ix ed  g en tly  fo r  2 0  s an d  the  
reac tio n  te rm in a ted  by the add ition  o f  sod ium  m etab isu lp h ite /d is tilled  w a te r 
(10  (il o f  15 m g /500  (il). T he tube w as p laced  in  an ice bath.
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D ) C o u p lin g  o f  ac tiv a ted  an d ro s ten ed io n e  to  io d in a ted  h is tam in e : S o d iu m  
h y d ro x id e  0 .2  M  (10  (il) w as added  to  the  io d in a tio n  m ix  fo llo w ed  by  the 
ac tiv a ted  an d ro s ten ed io n e  (50 (il). T h e  tube  co n ten ts  w ere  v o rtex ed  
p rio r to  incubation  at 10 ° C  fo r at least 1 h.
E ) P u rifica tio n  o f  io d in a ted  stero id : Io d in a ted  an d ro sten ed io n e  w as p u rified  
by  ad d in g  1 m l o f  each  o f  tw o  reag en ts , h y d ro ch lo ric  ac id  0.1 M  an d  e th y l 
aceta te , w ith  v o rtex in g  afte r each  addition . W hen  the tube con ten ts  se ttled  in to  
2 ph ases , the  u p p er o rg an ic  lay er w as rem o v ed  and  d iscarded . A fte r  each  1 m l 
ad d ition  o f  the  fo llo w in g  reag en ts , sod ium  h y d ro x id e  0.1 M , p h o sp h a te  b u ffe r 
p H  7 .0  and  e th y l ace ta te , the  tubes w ere  v o rtex  m ixed . T h e  tu b e  co n ten ts  
w ere a llow ed  to  settle  and  the  u pper o rgan ic  layer w as rem o v ed  in to  an o th er glass 
tube  co n ta in in g  an h y d ro u s so d ium  su lphate  (5 m g). T he e th y l ace ta te  ad d itio n  
w as repea ted  tw ice and the organ ic layers pooled. A fte r m ix ing  w ith  anhydrous 
so d iu m  su lp h a te , the  p o o led  o rg an ic  ex trac ts  w ere  rem o v ed  in to  an o th e r g lass 
tube. T he  ex trac t w as evapora ted  to 300 (il un d er a stream  o f  air, by  p lac in g  the 
tu b e  on  a h o t p la te  se t a t 37 ° C .  U s in g  a g lass  c a p illa ry  tu b e , [1 2 5  j]_ 
a n d ro s te n e d io n e  (1 0 0  (il) w as s trea k ed  ac ro ss  each  o f  3 T .L .C . p la te s , 
ap p ro x im a te ly  2 cm  fro m  the  b o tto m . T h e  3 p la te s  (u p rig h t, o rig in  at the  
b o tto m ) w ere  d ev e lo p e d  in  a so lv en t m ix tu re , ch lo ro fo rm : m eth an o l: acetic  
ac id  (90:10:1  by  v o lu m e) fo r 90  m in. T h e  p la tes  w ere  rem o v ed , a ir d ried , and  
p laced  (face  up, o rig in  first) on  a rad io ch ro m ato g ram  scan n er a t speed  se ttin g  1; 
ra n g e  100 K ; g asflo w  6 .5  and  tim e  K  set a t 10. E ac h  T .L .C . p la te  w as 
m a tc h e d  w ith  th e  re su ltin g  c h a rt re c o rd e r  tra c in g  (F ig . 10.) an d  th e  s ilic a  








FIG.  10.  R a d i o c h r o m a t o g r a p h i c  s c a n s  o f  T . L . C .  p l a t e s  a f t e r
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d e v e l o p m e n t  o f  I - h i s t a m i n e - a n d r o s t e n e d i o n e - t r a c e r s  .
(O) O r i g i n .
T h e  sc rap in g  o f  s ilic a  w as ca rried  ou t in  a p o ly th en e  bag  w ith in  a d e s ig n a te d  
F u m e cu p b o a rd  fo r safe ty  reasons. T h e  silica  w as p laced  in  a g lass  tube  and  
e lu ted  3 tim es w ith  e th an o l (1 m l). T he co m b in ed  e lu a te s  w ere  p lace d  in  a 
sc rew  cap  g la ss  tu b e  an d  s to red  a t 4  ° C .  T h is  p u r if ie d , io d in a te d  
androstened ione p repara tion  w as stable fo r at least 8 w eeks.
F ) W o rk in g  so lu tio n  fo r R IA : T h e  v o lu m e  o f  s tock  so lu tio n  c o n ta in in g  the 
req u ired  coun ts w as evaporated  to  dryness in a 50 m l conical flask  u n d er a stream  
o f  air. T h e  v o lu m e o f  R IA  buffer req u ired  to  g ive 10,000 cp m /2 0 0  |i l  (i.e. cpm  
p e r  R IA  tube) w as added . T o ta l co u n t tubes (T C ), c o n ta in in g  o n ly  lab e lled  
androstened ione , w ere  included  in each R IA  to quan tita te  the am oun ts o f  labe lled  
an d ro s te n e d io n e  ad d ed  to  each  assay  tube. T h ey  d id  n o t u n d e rg o  th e  w ash  
p ro ced u re .
2.3.5. Solvent Extraction of Androstenedione from Samples
A ) E x trac tio n  o f  A 4  fro m  serum  sam ples: S am ple  (50  |i l )  p lu s  d is tilled  w a te r 
(50  fil) w as added  to  a 10 m l g lass tube (100x16  m m ). H ex an e :e th e r (3 m l o f  
4:1 by  v o lu m e) w as ad d ed  using  a Z ip p ette  R ep ea tin g  P ipe tte . T h e  tu b es  w ere  
m ix ed  o n  a  M u lti-T u b e  V o rtex e r o p era ted  a t speed  4  fo r 4  m in . T h e  low er, 
aq u eo u s  p h ase  w as fro zen  by im m ersin g  the lo w er p a r t o f  the  tu b e  in  a b a th  o f  
so lid  ca rb o n  d io x id e  in m ethano l. T h e  up p er hexane: e th e r p h ase , co n ta in in g  
ex tra c ted  ste ro id , w as d ecan ted  ca refu lly  in to  a g lass  tu b e  (5 m l, 7 5 x 1 2  m m ). 
F o r  each  e thano lic  standard , 20  p i  w as added  to  a g lass tube  fo llo w ed  by so lven t 
(3 m l). S o lven t from  all tubes w as evaporated  on a B u ch le r V o rtex -E v ap o ra to r 
at speed  setting  4  un d er a vacuum  at 45 °C .
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B ) E x trac tio n  o f  A 4  from  d ried  b lood  spots: A  d isc  (5 m m  d iam ete r) w as
pu n ch ed  from  a d ried  b lood  spot in to  a 10  m l glass tube (100x16  m m ) and  e lu ted  
o v e rn ig h t w ith  sa line  (100  fil) at 2 2  ° C . S o lv en t w as ad d ed  an d  th e  tu b es 
m ix ed  at speed  2 fo r 8 m in  p rio r to cen trifu g atio n  on a C en tau r cen trifu g e  fo r 2 
m in  at 1 ,000 r.p .m . T he aqueous ph ase  w as frozen  and  the m eth o d  co n tin u ed  
as above y ie ld ing  glass tubes con tain ing  d ried  extracts.
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C H A P T E R  3. E V A L U A T I O N  O F R E A G E N T S :  
E X P E R I M E N T S  A N D  R E S U L T S
A n ti sera  w ere  a sse ssed  by  titre  and  sp ec ific ity . In itia l A b  titre  ex p e rim en ts  
(sec tio n  3 .1 .) u tilised  a so lid  p h ase  second  A b  sep a ra tio n  m eth o d . A  m o re  
c o n v e n ie n t m e th o d  o f  sep ara tio n  w as ach iev ed  by  en cap su la tin g  an tib o d ies  in 
sem i-p erm eab le  spheres. H ow ever, since m icro en cap su la tio n  o f  serum  fro m  all 
b leed s w as no t p rac tica l, on ly  an tisera  w ith  a titre  > 1 /4 ,0 0 0  w ere  se lec ted  fo r 
m icro en cap su la tio n . C o m b in a tio n s o f  m icro en cap su la ted  A b  an d  label, w h ich  
p ro d u c e d  sen s itiv e  s tan d ard  cu rv es, w ere  u sed  in  c ro ss  re ac tio n  s tu d ies  w ith  
re la ted  stero ids to assess specific ity  (section 3.2.).
3 .1 .  A n t i b o d y  T i t r e .
A n tise ru m  w as d ilu ted  1/100 to  1 /80 ,000  w ith  R IA  buffer. A n tib o d y  d ilu tio n  
cu rv es  w e re  d e r iv e d  u sin g  a so lid  p h ase  seco n d  an tib o d y  sep a ra tio n , T ab le  5. 
T h e  a n tise ru m  d ilu tio n  w h ich  g av e  a B /T  o f  50%  w as c a lc u la te d  fro m  th e  
an tib o d y  d ilu tio n  cu rv e  and  th is titre  d e term in ed  the v o lu m e o f  an tise ru m  to  be 
en cap su la ted . A n tib o d y  titres fo r all co m b in a tio n s  o f  an tib o d y  and  lab el w ere  
m o n ito red  in  each  an im al du ring  one year. In  an im als that p ro d u ced  m easu rab le  
an tibody  titres, the titres increased  during  the first six m onths and rem ain ed  fa irly  
constan t th ereafter (T able 6).
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Table 5. Protocol for the construction of androstenedione (A4 ) 
antibody dilution curves.
V olu m e (jil)





A b D ilution 
C urve
A b
125I-A 4 (10 ,000  cpm ) 100
Incubated  overn ight at 22 °C
100
100
Solid phase A b-2
*Incubated  60 min at 22 °C
200
W ash solution - 3 ,0 0 0
C en trifuged  at 2 ,000  rpm  fo r 3 m in  at 4 °C . Supernatan t asp ira ted , d iscard ed  
and w ash repeated  tw ice. P recip itates w ere counted  and A b d ilu tion  curves 
construc ted .
(A b-2) S econd an tibody. (*) W ith  shaking.
Table 6 . Antibody titres* ( x 10~3) as determined by incubating 
antibodies raised against immunogens linked to androstenedione 
(A4 ) at positions 3, 6 and 11 with similarly linked androstenedione 
iodohistamine labels.
1 2 5 i . A 4 label
I m m u n o g e n  A nt ibody -3C M O -6(3H S - l l a H S
A 400 _ 3.7
-3C M O  B 65 - -
C 130 - 4 .2
D _ -
-6 p H S  E ------d ied -
F 11 -
H - - 40
-1 l a H S  I - - 85
J 280
(*) T itre  is the d ilu tion  required  to ensure a b ind ing  o f  50  p ercen t o f  label. 
(-) B ind ing  < 4 x 10"3 (-3C M O ) -3 -C arb o x y m eth y lo x im e.
(-6[3HS) -6 p -H em isu cc in a te . (-1 la H S )  -1 la -H e m isu c c in a te .
R ab b it D  fa iled  to  p ro d u ce  an tiserum  able to b ind  to  any  o f  the io d h is tam in e  A 4  
rad io lig an d s , and  rab b it E  d ied  from  u n k n o w n  causes; bo th  are o m itted  fro m  
T ab le  6 . R ab b its  A , B an d  C , im m u n ised  w ith  A 4 -3 C M O -B S A , p ro d u c e d  
an tise ra  o f  h igh  titre  w ith  125 I-A 4 -3 C M O  label. T h ese  an tise ra  p ro d u c ed  no  
b in d in g  w ith  ^^^I-A.4 -6 pH S label and  on ly  A b  C b ound  125j_A4-1 l a H S  label 
w ith  a m o d e ra te  titre . R ab b its  D  and  F , im m u n ised  w ith  A 4 - 6 P H S -B S A , 
p ro d u c e d  an tise ra  w h ich  d id  no t b in d  1 2 5 i_ A 4 -3 C M O  o r  1 2 5 i_ A 4 -1  l a H S  
lab e ls , a n d  o n ly  an tib o d y  F  had  a h igh  titre  w ith  the  1 2 5 i_ A 4 ~ 6 p H S  lab el. 
R ab b its  H , I and  J, im m u n ised  w ith  A 4 - I  la H S -B S A , p ro d u ced  an tise ra  o f  h igh  
titre  w ith  125j_A 4-1 l a H S  label bu t no  b in d in g  w ith  125 i_A 4-3C M O  o r  125j_ 
A 4 - 6 P H S  lab e ls . R esu lts  illu s tra te  th a t titre  is v a r ia b le  an d  d e p e n d s  o n  th e  
p o sitio n  o f  the iodoh istam ine linkage to A 4  and  the position  o f  linkage o f  BS A  in  
the im m unogen .
3.1.1. Suitable Antisera for M icroencapsulation
In  ca se s  w h e re  titre  w as > 1 /4 ,0 0 0 , an tise ra  w ere  e n c ap su la ted  an d  p o ss ib le  
d isp lacem en t o f  the rad io lig an d  by u n lab elled  A 4  w as investiga ted . A b 's  A , B , 
C; F ; an d  H , I, J w ere m icro en cap su la ted  fo r eva lua tion  w ith  12 5 i-A 4 -3 C M O ; 
125j_A 4-6pH S  o r 1 2 5 ^ 4 - 1  la H S  labels.
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3.1.2. Selection of Microencapsulated Ab (Mic.Ab) Dilution
M icro e n cap su la te d  A b p rep ara tio n  w as d ilu ted  1/5 to  1 /160 w ith  R IA  buffer. 
D ilu tio n s  o f  m icro en cap su la ted  A b ’s A , B, and  C  w ere  in cu b ated  w ith  l 2 5 l-A 4 - 
3C M O  label. D ilu tio n s o f  m icro en cap su la ted  A b  F  w ere  in cu b a ted  w ith  125j_ 
A 4 -6 PH S label. D ilu tio n s  o f  m ic ro e n cap su la ted  A b 's  H , I, J an d  C  w ere  
in cu b a te d  w ith  ^ ^ I - A 4 - l l a H S  label. A  m ic ro cap su le  d ilu tio n  cu rv e  w as 
p ro d u ced , T ab le  7 , an d  sep a ra tio n  o f  bo u n d  and  free  frac tio n s  w as ach iev ed  by 
cen trifugal p recip ita tion  o f  m icrocapsules. T he d ilu tions o f  m icroencapsu la ted  
A b 's  g iv in g  a B /T  o f  40% , show n in  T ab le  8 , w ere  ca lcu la ted  fro m  the  d ilu tio n  
cu rv e s  a n d  w e re  u sed  in  the  fo llo w in g  d o se - re sp o n se  an d  c ro ss  re a c tio n  
experim en ts.
3.1.3. Comparison of Standard Curves for Combinations of Ab and 
Label
D o s e - re s p o n s e  c u rv e s  (T a b le  9 ) w e re  o b ta in e d  b y  in c u b a t in g  th a w e d  
an d ro sten ed io n e  standard  so lu tions (200 p.1) w ith  m icro en cap su la ted  A b ’s A , B, 
C; F ; an d  C , H , I, J w ith  the labels , 1 2 5 l -A 4 -3 C M O ; 1 2 5l-A 4-6 (3H S ; and  
l 2 5 l - A 4 " l l a H S  re sp ec tiv e ly . T h e  re su ltin g  s tan d a rd  cu rv es  a re  sh o w n  in  
Fig . 11. M icro en cap su la ted  A b 's  A , B and C  w ith  the  ^2 ^I-A 4 -3 C M O  label
g av e  th e  m o s t sen sitiv e  s tandard  curves. S en sitiv e  s tan d ard  cu rv es  w ere  a lso  
o b ta in ed  w ith  m ic ro en cap su la ted  A B 's C  and I and  the ^2 ^I-A 4~1 l a H S  
label. A  less sensitive  standard  curve w as p rod u ced  by m icro en cap su la ted  A b  F  
w ith  the  l 2 5 l-A 4 -6 pH S  label.
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Table 7. Protocol for the construction of dilution curves with 
antibody-containing microcapsules.
V olum e (|dl)
F o r F o r
Tubes Total M ic.A b D ilution
C ounts C urve
M ic.A b 2 0 0
1 2 5 I-A 4  (10 ,000  cpm ) 2 0 0 2 0 0
B u ffe r 2 0 0
*Incubated 45 min
W ash  solution 3 ,0 0 0
C en trifuged  at 2 ,000 rpm  for 3 m in at 4 °C . P recip itates w ere rew ashed  and
coun ted . M ic.A b dilu tion  curves w ere constructed .
(*) In  a 37 °C  w ater bath. (M ic.) M icroencapsulated .
Table 8 . Summary of dilutions of microcapsules at which 
androstenedione (A4 ) antibodies bind 40 percent of the label.
1 2 5 i - A 4 label
I m m u n o g e n M ic .A b -3C M O -6p H S  - l l c x H S
A 1/40
-3C M O B 1 /1 0 0 - -
C 1/80 - 1 /10
- 6 p H S F - 1/150 -
H - - 1/40
-1 l a H S I - - 1 /1 1 0
J 1 /10
(M ic.) M icroencapsu la ted . (-3C M O ) -3 -C arboxym ethyloxim e. 
(-6P H S ) -6(3-H em isuccinate . (-1 l a H S )  -1 la -H e m isu c c in a te .
Table 9. Protocol for the construction of androstenedione (A4 ) dose- 
response curves.
T u b e s
Volum e (pi)
F o r F o r 
Total A 4  S tandard 
C ounts C urve
S tandard 2 0 0
125 i -a 4 2 0 0 2 0 0
M ic.A b
*
Incubated  45 m in
2 0 0
W ash  solution - 3 ,0 0 0
C en trifu g ed  at 2 ,000 rpm  for 3 m in at 4 °C . P recip itates w ere rew ashed  and 
coun ted . D ose-response curves w'ere constructed .
(*) In a 37 ° C  w ater bath. (M ic.) M icroencapsulated .
Fig. 11. Comparison of dose-response curves for different 
combinations of [125i]-racJiolabels and microencapsulated antibodies. 
Separation of antibody-bound from -free fractions was achieved by 
centrifugation of microcapsules.
Androstenedione standard solutions were incubated with:
-3CMO label and -3CMO antibodies A, B and C (top panel);
-6 pHS label and -6 pHS antibody F (middle panel); and 
-1 laH S  label and -1 laH S  antibodies H, I and J 
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In se n sitiv e  s tan d ard  cu rv es w ere  p ro d u ced  by  m ic ro en cap su la ted  A b 's  H  
and  J w ith  the  ^ ^ I - A 4 - l  l a H S  label. N o fu rth e r ex p e rim en ts  w ere  ca rried  ou t 
w h ich  in v o lv ed  A b 's  F , H  and  J b ecau se  o f  the  in sen s itiv e  s tan d a rd  cu rv es  
w h ich  resu lted . A  sum m ary  o f  sensitiv ities is g iven in T ab le  10.
3.2.  A n t i b o d y  S p e c i f i c i t y .
C ro ss  re a c tio n  w ith  21 re la te d  s te ro id s  w as s tu d ied  in  sy s tem s  w h e re  
se n s itiv ity  w as < 1 5  p g  (d e fin ed  as a 10%  d ec rea se  in b in d in g  o f  th e  ze ro  
standard) by the m ethod  ou tlined  by  A braham  et a l A ^
i) In itia l c ro ss  reac tio n  study: E ach  co m p etin g  stero id  (30 ,000  p g /2 0 0  |i l)  and  
an d ro s ten ed io n e  s tandard  w as assay ed  as show n in T ab le  9 and  the v a lu e  B /B o  
w as ca lcu la ted . T h o se  co m p e tin g  ste ro id s w h ich  had  a B /B o  > 50%  and  
h en ce  a c ro ss  reac tion  < 0 .5 %  w ere  not in vestigated  fu rther. C o m p etin g  
s te ro id s  w h ich  had  a B /B o  < 50%  and , th e re fo re , a c ro ss  re ac tio n  > 0 .5%  
w ere investigated  in m ore  detail to  determ ine the exact cross reaction.
ii) F in a l c ro ss  re ac tio n  study: A s ste ro id s cross re ac t to  d iffe ren t d eg rees  e.g . 
w ith  m o d est o r  h igh  co m p etitio n , it w as n ecessary  to co n stru c t a s tan d ard  cu rve  
co v e rin g  the  ap p ropria te  range. A  range  o f  stero id  co n cen tra tio n s  (A  o r B ) w as 
se lec ted  (T ab le  11): R an g e  A  fo r s te ro id s  w h ich  sh o w ed  m o d est co m p e titio n  
(c ro s s  re a c t io n  > 0 .5 % ), an d  R a n g e  B fo r  s te ro id s  w h ic h  sh o w e d  h ig h  
co m p etitio n  (cross reac tion  »  0 .5% ).
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Table 10. Summary of androstenedione standard curve 
sensitivities* (pg).
I m m u n o g e n M ic .A b
1 2 5 I .A 4  label
-3CM O - 6 p H  S - l l a H S
A 3.6
-3C M O B 4.8 -
C 3.6 13
-6 P H S F - 26
H 70
-1 la H S I - 9
J - 68
(*) Sensitiv ity  is the am ount o f  unlabelled antigen req u ired  to p roduce 
a 10 percent d rop  in the binding o f  the zero standard. (M ic.) M icro en cap ­
su lated . (-3C M O ) -3 -C arboxym ethyloxim e. (-6(3HS) -6P -H em isucc ina te . 
(-11 a H S )  -11 a -H em isu cc in a te .
Table 11. Serial doubling dilutions of standard solutions 
of steroids which cross react with modest competition 
(type A; 30,000 pg/200 pi) or with high competition 
(type B; 20,000 pg/200 pi).
Steroid  Type (pg)





4 3 ,7 5 0 1,250
5 7 ,5 0 0 2,500
6 15,000 5,000
7 3 0 ,0 0 0 1 0 ,0 0 0
8 2 0 ,0 0 0
D o se-resp o n se  cu rves w ere derived  w ith the standard  o r com p etin g  stero id  by  the 
m ethod  ou tlined  in T ab le  9. T he standard  curves w ere co n stru c ted  and  the m ass 
o f  each  c o m p e tin g  s te ro id  n eed ed  to  d isp lace  50%  o f  th e  b o u n d  la b e lle d  
a n d ro s te n e d io n e  w as d e te rm in ed . C ro ss  re ac tio n s  w e re  ca lc u la te d  fo r th e  
co m p etin g  stero ids and the resu lts are show n in T ab le 12.
S te ro id s  w h ich  ex h ib ited  h igh  cross reac tio n  w ere  5 a -a n d ro s ta n -3 , 17- 
d io n e  a n d  l ,4 - a n d r o s ta d ie n - 3 ,1 7 - d io n e  fo r  a ll  a n t ib o d ie s  te s te d .  
A n d ren o ste ro n e  show ed  h igh cross reaction  w ith  m icro en cap su la ted  A b 's  C  and  
I w ith  11 cxHS label and m odera te  in terference w ith  m icro en cap su la ted
A b  C and  125j_A 4-3C M O  label. T h is illustra tes the im p o rtan ce  o f  the  linkage 
p o s itio n  o f  io d o h is ta m in e  to  the  s te ro id  n u c leu s , w h ich  is th e  o n ly  d iffe ren c e  
b e tw een  th ese  tw o  system s and  yet, th ere  is a m ark ed  d iffe ren c e  in  spec ific ity . 
H ig h  c ro s s  re a c t iv i ty  w a s  sh o w n  b y  5 P - a n d r o s t a n - 3 ,1 7 - d io n e  w ith  
m ic ro e n cap su la ted  A b  B an d  125 i_A 4-3C M O  label an d  m o d era te  c ro ss  
re ac tiv ity  w ith  m ic ro en cap su la ted  A b  C w ith  bo th  labels. T h ese  fin d in g s  a re  
show n  in F ig . 12. M in o r in te rfe ren ce  w as show n by  e tio ch o lan o lo n e  w ith  
m ic ro e n cap su la ted  A b  C and  125 i_A 4-3C M O . T h ese  fin d in g s  sh o w  th a t 
m ic ro e n cap su la ted  A b  A  has th e  lea s t in te rfe ren c e  fro m  co m p e tin g  ste ro id s . 
A n tib o d y  I w ith  ^ ^ I - A 4 - l  l a H S  system  w as no t ev a lu a ted  fu r th e r b ecau se  o f  
p o o r d isp lacem en t o f  label o v er the range o f  concen tra tions o f  A 4  likely  to  o ccu r 
in p a tien ts ' sam ples.
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Table 12 . Cross Reaction* Studies
Assay System'*'
A ,3/3 B.3/3 C.3/3 C.3/11 1, 11/11
Androstenedione 100 100 100 100 100
5a-androstane - 3,17-dione 37 42 40 26 17
1,4- a ndros tadie ne - 3 ,17-di one 18 56 43 27 25
4-androstene-3 ,l 1,17-tnone 1 3 5 38 31
5 p- androstane - 3,17 -dione 2 21 6 6 2
5 a-an d ro s tan e -3 a ,1 7 a-d io l, <0.5 in all systems
5 a - androstane- 3a , 17 (3-diol,




11 -deoxycorticosterone, cortisol, progesterone,
17-hydroxyprogesterone, 17P-oestradiol
(*) All results expressed as % cross reactivity= [(mass o f A4 required to displace 50% of bound 
labeled A4 /  m ass o f steroid under test required to displace 50% of bound labeled A4 )] x 100. 
(♦) Rabbit, and position of attachment to steroid nucleus o f immunogen;'' label.
Fig. 12. Steroids showing major cross reacton with androstenedione (A 4 ) 
antibodies with 125j_A4-3CMO or 125i_A4-3CMO label.
A4-3CMO antibodies A and B with a ^ 5 j_A4-3CMO label;
A4-3CMO antibody C with 125i-A4-3CMO or 125j_A4-1 laH S label and; 
A4 - l la H S  antibody I with 125i_A4-llaFIS label.
Results are expressed as percent cross reacton on the basis that 
androstenedone cross reacts 100% with androstenedione antibody.
1MHUN0 0£N A
6 S A 1 i n k e c t o  A4  a t  p o s i t i o n  3
I 0 0 0 HI STAMI NE
1 1




1 0 0  1 0 0  1 0 0  1 0 0  1 0 0
5<2- ANDR0STANEDI 0NE
3 6 . 6  4 2 . 0  4 0 . 4  2 6 . 3  1 7 . 1
1 , 4 - A N D R O S T A D I E N E - 3 , 1 7 - DI ONE
1 7 . 9  5 6 . 2  4 2 . 7  2 7 . 4  2 4 . 6
4 - ANDROSTEN- 3 , 1 1 , 1 7 - TRI  ONE 
( A d r e n o s t e r o n e )
5 / 3 - ANDROS TAN- 3  , 1 7 - DI ONE
0 . 7  2 . 7  5 . 4  3 8 . 4  3 1 . 1
2 . 1  2 1 . 3  5 . 7  6 . 2  2 . 1
3.3. A n  A l t e r n a t i v e  ( s e c o n d  a n t i b o d y )  S e p a r a t i o n  M e t h o d
A n  a lte rn a tiv e  m e th o d  o f  sep a ra tin g  bound  an d  free  fra c tio n s  u s in g  a so lu b le  
seco n d  an tib o d y  (A b-2), d onkey  an ti-rabb it IgG , w as in v es tig a ted  b ecau se  the 
m ic ro cap su le  d ilu tio n  o f  A b C  used  w ith  l a H S  w as  low  an d
w a s te fu l o f  an tib o d y . D o n k e y  an ti-ra b b it Ig G  an d  n o rm a l ra b b it  se ru m  
(D A R /N R S ) d ilu tio n s  w ere  o p tim ised  and  an tib o d y  titre s  w ere  re a sse sse d  fo r 
each  an tiserum  pool.
3.3.1. Determination of the Soluble Second Antibody Dilution
D A R  an d  N R S w ere d ilu ted  w ith R IA  buffer 1/2 to  1/640, respec tive ly . A  
d i lu tio n  c u rv e  fo r  D A R  a t each  N R S  d ilu tio n  w a s  o b ta in e d , T a b le  13. 
D ilu tio n s o f  D A R  and NRS w ere op tim ised  and second an tibody  so lu tion  (400 p.1 
o f  a m ix tu re  o f  1 /40 D A R  and  1 /500  N R S in  assay  b u ffe r) w as  u sed  in  all 
fo llo w in g  experim en ts  to  separate bound and  free  fractions.
T h is w as p rep ared  by m ix in g  R IA  buffer w ith  don k ey  an ti-rab b it an tise ru m  and  
add ing  norm al rabbit serum  im m ediately  before use. V olum es w ere chosen  so that 
1 1 o f  reag en t w ould  con tain  25 m l o f  an tiserum  and  2 m l o f  no rm al rab b it serum . 
T h e  am o u n t o f  re a g e n t p re p a re d  w as  se t b y  th e  n u m b e r  o f  sam p le s  to  be  
determ ined .
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Table 13. Protocol for the construction of a dilution curve with 
soluble second antibody.
V o l u m e  ( j i l )
F o r





A b C (  1/20,000)
1 2 5 I-A 4 - l l a H S  (10 ,000  cpm ) 200
2 0 0
2 0 0
* Incubated 45 m in
D A R +  IgG 
N R S + +
2 0 0
2 0 0
Incubated  overn ight at 4 ° C
C entrifuged  at 3 ,000  rpm  for 60 m in at 4 °C . S upernatan ts  asp ira ted  carefu lly  
and d iscarded . The precip ita tes w ere coun ted  and D A R /N R S  d ilu tion  
ch equerboard  constructed .
(*) In a 37 ° C  w ater bath. (+) D onkey  an ti-rabb it. (++ ) N orm al rabb it serum .
3.3.2. R eassesm ent of Antibody Titre Using a Soluble Second  
Antibody Separation
T h ree  p o o ls  o f  an tise ra  (A , B and C ) w ere  p rep ared  b y  m ix in g  a v o lu m e  o f  
se ru m  (1 m l) fro m  each  h igh  titre  b leed . E ach  p o o l w as d ilu te d  1/100 to  
1 /1 6 0 ,0 0 0  w ith  R IA  buffer. A n tib o d y  d ilu tio n  cu rv es  w ere  d e riv e d  by  the
m eth o d  show n in T ab le  14. T h e  titres  fo r an tise ra  p o o ls  w ere  100, 50, 60
and  20  x 10" 3 fo r A b 's  A , B a n d  C each  w ith  125 j _A4_3c m o  label an d  
A b  C  w ith  125 i _A4_1 I qcH S, respectively .
3.4 .  M e a s u r e m e n t  o f  A n d r o s t e n e d i o n e  i n  S e r u m
T o  o b ta in  m o re  in fo rm a tio n  o n  sp ec ific ity , p a tien ts ' se ru m  sam p les  w e re  
an a ly sed  and  the  re su lts  w ere  co m p ared  to  the ro u tin e  m eth o d , w h ich  is b ased  
on a tritia ted  rad io ligand .
3.4.1. Comparison of RIA Systems
A n d ro s te n e d io n e  w as ex tra c ted  fro m  seru m  sam p les  th en  m easu red  by  fo u r 
d iffe ren t R IA  system s, A b 's  A , B , and C  each  w ith  125 i_A 4-3C M O  and  
A b  C  w ith  1 2 5 i_ A 4 -1  l a H S .  T h e  R IA  p ro c ed u re  is  sh o w n  in  T ab le  15. 
C o n cen tra tio n s  o f  A 4  ob ta in ed  v ary  g rea tly  d ep en d in g  on the re ag en ts  used , 
although  sensitiv ity  and specificity  studies o f  the reagen ts are sim ilar.
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Table 14. Protocol for the construction of dilution curves for 











125i_A4 ( 1 0 ,0 0 0  cpm ) 2 0 0




Incubated  overn ight at 4 °C
400
C en trifuged  at 3 ,000 rpm  for 60 m in  at 4 °C . Supernatan t w as ca re fu lly  asp ira ted  
and discarded . T he precip ita tes w ere counted  and A b dilu tion  cu rv es construc ted .
(*) In a 37 ° C  w ater bath. (A b-2) S econd antibody.
Table 15. Protocol for the measurement of androstenedione 
(A4 ) in serum samples by radioimmunassay following solvent 
extraction.
V o l u m e  ( ja l )
F o r F o r 
Total A4  S tandard  




S erum  sam ple in 10 ml tube 50
E thanolic
s tandard  in 5 ml tube - 50 -
H ex an e:e th er
(4:1 by vo l.) - 3 ,0 0 0 3 ,0 0 0
V o rtex  sam ple tubes for 4 m in. D ecan t solvent phase  in to  5 m l tubes fo llow ing  
im m ersion  in a bath o f  solid carbon dioxide in m ethanol. E vaporate so lv en t'1' 
from  all tubes.
A b - 200 
125I-A 4  (10 ,0 0 0  cpm ) 200  200
2 0 0
2 0 0
* Incubated  45 m in
S olub le  A b -2  - 400 400
Incubated  overn igh t at 4 ° C
C en trifu g ed  at 3 ,000 rpm  for 60 m in at 4 °C . S uperna tan ts asp ira ted  carefu lly  
and  d iscarded . The precipitates coun ted  and d ose-response curve constructed .
(+) U n d e r a vacuum  at 45 °C . (*) In a 37 ° C  w ater bath. 
(A b-2) S eco n d  antibody.
T h e  re su lts , sh o w n  in F ig . 13, a re  co m p ared  ag a in s t the  ro u tin e  m eth o d . 
A n d ro s te n ed io n e  w as m easu red  aga in  in  sam ples b y  tw o  sy s tem s A b  C  w ith  
1 2 5 l-A 4 -3 C M O  o r 125 i_A 4 -1  l a H S .  H o w ev er, to  re d u ce  sen sitiv ity  in  the  
system  em p lo y in g  ^ ^ I -A 4 -3 C M O , the vo lu m e o f  serum  w as d ecreased  to  
2 0  p i. T he  resu lts  are sim ilar w hen A b C  is used  w ith e ith e r label.
3.4.2. Final Selection of RIA System
1 2 5 l-A 4 -3 C M O  w as se lec ted  o v e r l a H S  w h en  u sed  w ith  A b  C
b e c au se  o f  b e tte r  sen s itiv ity  (req u irin g  o n ly  2 0  p i  o f  sam p le) an d  a b e tte r  
co rre la tio n  w ith  the ro u tin e  m ethod . A  larger co m p ariso n  b e tw een  the se lec ted  
m e th o d  an d  th e  "in  h o u se"  m e th o d , c o n d u c te d  w ith  58 p a tie n ts ’ sam p le s , 
co n firm e d  p re lim in a ry  find ings. T h e  co rre la tio n  co e ffic ien t w as 0 .9 4  w ith  a 
s lo p e  o f  1.02 an d  an in te rcep t o f  0 .9  nm ol/1, co m p ared  w ith  0 .9 6 , 1 .02,
and  1.1 n m o l/1, re sp ec tiv e ly , fo r the p re lim in ary  study. G o o d  co m p ariso n  w as 
o b ta in ed  o n ly  i f  hex an e ie th er (4:1 by vol.) w as used  as the ex trac tio n  so lv en t fo r 
the  m eth o d  w ith  rad io io d in e  label. I f  e th er a lone w as used  resu lts  o b ta in ed  w ere 
co n sid erab ly  h igher.
3.4.3. Measurement of A4 in Serum Samples by Direct Means
T h e  se lec ted  m eth o d , A b  C in co m b in a tio n  w ith  ^2 ^ I-A 4 -3 C M O  u sin g  a 
so lub le  second  an tibody  separation  stage, w as applied  to  the m easu rem en t o f  A 4  
d irec tly  in  se ru m  w ith o u t p rio r so lv en t ex trac tio n  by  the  p ro c e d u re  sh o w n  in 
T ab le  16. A ll A 4  lev e ls  w ere  g rea te r than  28 nmol/1. T h is  ex p e rim en t w as 
rep ea ted  using  the selected  reagents at low  pH  (C itrate bu ffer pH  4.0) to avo id
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Fig. 13. Comparison of serum androstenedione results obtained by a 
reference method with a tritium label and by radioimmunnoassays with 
four different combinations of antiserum and iodinated radioligands. 
Androstenedione (A4 ) was extracted from serum samples and measured 
by a reference method and four different RIA systems. The latter 
employed a soluble second antibody to separate antibody-bound from 
the -free fracton. The four RIA systems were based on antibodies A, B 
and C each with 125i-A4-3CMO label, coded A(3/3), B(3/3) and C(3/3), 
respectively and antibody C w'ith 125i_A4-1 la H S , coded C (3 /l l) .  




































Table 16. Protocol for the direct measurement of androstenedione 
(A4 ) in serum samples by radioimmunoassay without solvent 
extraction.
Tubes
V o lu m e  (fil)
F or F or 
Total A 4  S tandard 




E thanolic standard 5
Evaporate to dryness
C harcoal stripped  serum  - 5 -
Serum  sam ple - 5
R IA  buffer 50 50
Incubated overn igh t at 22 °C
1 2 5 I-A 4 - 3 C M O  (10 ,000  cpm ) 200  200 2 0 0
Incubated 2 hours at 22 ° C
Soluble A b-2 400 400
Incubated overn igh t at 4 °C
C en trifuged  at 3 ,000  rpm  for 60 m in at 4 °C . S upernatan ts carefu lly  asp irated
and d iscarded . T he precip itates w ere counted.
(A b-2) S econd  antibody.
p ro b lem s w ith  specific  stero id  b ind ing  pro teins. A ga in  , all co ncen tra tions w ere 
g rea te r than  28 nmol/1. R esu lts  show ed  that it w as no t p o ssib le  to  m easu re  A 4  
d irec tly  in serum  u sin g  th is m eth o d  and  hence no  fu rth e r study  w as a ttem p ted  in  
th is area.
3 .5 .  M e a s u r e m e n t  o f  A n d r o s t e n e d i o n e  i n  D r i e d  B l o o d  
S p o t s
A lth o u g h  th e  se le c te d  sy s tem  w as se n s itiv e  fo r a se ru m  R IA , fu r th e r  
im p ro v em en t in sen sitiv ity  w as so u g h t to  en ab le  the system  to  be ap p lied  to  the 
m easu rem en t o f  A 4  in  d ried  b lood  spots. A  d isc  (5 m m ) p u n ch ed  fro m  a d ried  
b lo o d  sp o t co n ta in s  the  eq u iv a len t o f  o n ly  3 |i l  o f  serum  and  th ere fo re  it w as 
necessa ry  to  o b ta in  the m o st sensitive  R IA  p o ssib le . T o  ach iev e  th is , an tise ra  
fro m  in d iv id u a l b leed s o f  rab b it C w ere  re assessed  to  d e te rm in e  i f  o n e  w o u ld  
p ro v id e  the  b as is  fo r  an  ev en  m o re  sen s itiv e  R IA . O n ce  a fu lly  o p tim ised  
sy s tem  w as se lec ted , m easu rem en t o f  A 4  in  d ried  b lo o d  sp o ts  fo llo w in g  
so lven t ex traction  and  by direct m eans w as investigated .
3.5.1. Comparison of Antisera from Individual Bleeds of Ab C
A n an tib o d y  d ilu tion  cu rve  w as ob ta ined  fo r the serum  from  each  o f  seven  b leeds 
o f  A b  C  (d en o ted  by A b  C - l ,  A b  C -2  etc ., to  A b  C -7) by  the m eth o d  show n  in 
T ab le  14. A n tib o d y  titre s  w ere  ca lc u la te d  and  d o se -re sp o n se  cu rv es  w ere  
d eriv ed  as show n in T ab le  17, u sing  each  an tibody  a t the ap p rop ria te  d ilu tion .
77
Table 17. Protocol for the construction of an androstenedione
(A4) dose-response curve for each bleed from rabbit C.
V o lu m e (jil)
F o r F o r
Total A 4  S tandard
T u b e s C ounts C urve
E thanolic  standard 2 0
E vaporated  to dryness
A b C-n - 2 0 0
1 2 5 I-A 4-3C M O 2 0 0 2 0 0
Incubated 2 hours at 22 °C
Soluble A b-2 - 400
Incubated overn igh t at 4 ° C
C en trifuged  at 3 ,000 rpm  for 60 m in at 4 °C . S upernatan ts asp ira ted  carefu lly
and  d iscarded . T he precip itates coun ted  and  dose-response  curves w ere
construc ted .
(A b-2) S econd  antibody.
(n) N u m b er 1 to  7 denoting  antisera from  each o f  seven bleeds.
T h e  sen s itiv ity  o f  each  re su ltin g  s tan d ard  cu rv e  w as c a lc u la ted  an d  the m o st 
sensitive  standard  cu rve  w as selected  fo r use w ith  125j_A 4-3C M O  in  m easu rin g  
A 4  in  d ried  b lood  spots by R IA . A n tibody  titres w ere in  the range  
12-17 x 10~5. T h e  sensitiv ity  o f  each  resu lting  standard  cu rv e  w as in  the range:
0 .2  - 0 .5  nmol/1. T h e  m o st sen sitiv e  standard  cu rv e  w as p ro d u c ed  by A b C -7 
an d  h en ce  th is  w as u sed  w ith  ^ ^ I - A 4 -3 C M O  to  m easu re  A 4  in  d ried  b lo o d  
spo ts by  R IA .
3.5.2. RIA for A4 Following Solvent Extraction from Dried Blood 
S p ots
A n d ro sten ed io n e  w as ex trac ted  in to  hexan ere th er (3 m l o f  4:1 v /v ) from  a d isc  
(5 m m ) p u n ch ed  o u t from  a series o f  b lood  spo t s tandards and  sam ples. U sin g  
th e  se lec ted  re ag en ts  (A b C -7 w ith  1 2 5 i _A4 -3 C M O ) a  R IA  w as ap p lied  to 
b lo o d -sp o t ex trac ts , as show n in T ab le  18.
3.5.3. M easurem ent of Androstenedione in Dried Blood Spots by 
Direct Means
A  d isc  (5 m m ) w as p u n ch ed  o u t fro m  a series o f  b lo o d -sp o t s tan d ard s  in to  a 
test tu b e  and  e lu ted  o v ern ig h t in saline (50 p i) a t 22  °C . U sin g  the o p tim ised  
R IA , A 4  w as m easu red  d irec tly  in b lo o d -sp o t e lu a te s  by  the  m e th o d  sh o w n  in 
T ab le  19.
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Table 18. Protocol for a radioimmunoassay for androstene­
dione (A4 ) in dried blood-spot extracts.
Volume (jil)
F o r F or 
Total A4  S tandard 
Tubes C ounts C urve
F o r
U n k n o w n
Sam ple
A 4  extract - + 
A b C-7 - 200 




Incubated  2 hours at 22 ° C
S oluble A b-2  - 400 400
Incubated  overn igh t at 4 ° C
C en trifuged  at 3 ,000 rpm  fo r 60 m in at 4 °C . S upernatan ts w ere asp ira ted , 
d iscarded  and the precip ita tes counted. The standard curve w as construc ted  
and the resu lts for sam ples w ere calculated .
(A b-2) Second antibody.
Table 19. Protocol for the construction of an androstenedione
(A4) dose-response curve in dried blood spots by direct means.
V o lu m e ( p i )
F o r
Total
T u b e s  C oun ts
F o r
A 4  S tandard 
C urve




Eluted overnight at 22 ° C
A b C-7
1 2 -‘’I-A 4 -3 C M O ( 1 0 ,0 0 0 cpm ) 200
2 0 0
2 0 0
Incubated 2 hours at 22 ° C
S oluble A b-2 400
Incubated overn igh t at 4  ° C
C en trifu g ed  at 3 ,000  rpm  for 60 m in at 4 °C . S uperna tan ts  w ere carefu lly  
asp ira ted  then discarded  and the precip ita tes coun ted . T he  dose-response 
cu rve  w as construc ted  and the results fo r sam ples w ere in terpolated .
(A b-2) S econd  antibody.
C H A P T E R  4. E V A L U A T I O N  O F  S E L E C T E D  A 4 
R IA  S Y S T E M : E X P E R IM E N T S  A N D  R E S U L T S
F o llo w in g  the ab o v e  p re lim in a ry  ev a lu a tio n  o f  reag en ts , A b  C  w ith  1 2 5 i _A4- 
3 C M O  lab e l, a m o re  d e ta iled  in v es tig a tio n  w as ca rried  out. T h e  p a ram ete rs , 
accu racy , p rec is io n , and  p a ra lle lism  w ere  in v es tig a ted  fo r th e  se ru m  an d  b lo o d  
spo t R IA  s.
4 .1 .  A c c u r a c y
T he ex traction  effic iency  w as determ ined  by m easu ring  the ana ly tica l reco v ery  o f 
A 4  fro m  serum . A  v o lu m e o f  s to ck  [3 H ]-A 4  w as ev a p o ra ted  in tw o  g lass  
tubes. A  v o lu m e (5 m l) o f  serum  o r  e th an o l w as ad d ed  to  each  tube  and  
the  tubes in cu b a ted  o v ern ig h t a t 22  °C . S erum  (20  p i)  w as ex trac ted  in to  
h e x a n e :e th e r  (3 m l o f  4:1 by v o lu m e) an d  tran sfe rre d  in to  sc in tilla tio n  v ia ls . 
S o lv en t (3 m l) w as a lso  added  to  v ia ls  co n ta in in g  [3 h ] - A 4  in  e th an o l (20  p i). 
S o lven t w as evaporated  from  vials u nder a stream  o f  a ir and scin tilla tion  flu id  w as 
a d d e d  (4  m l) th en  th e  c o n ten ts  m ix ed . B e ta -rad ia tio n  w as d e te c te d  on a 
sc in tilla tio n  coun ter. E x trac tio n  w ith  h ex an e :e th er gave a m ean  an a ly tica l 
re co v ery  o f  96%  (n=10).
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T h e  re c o v e ry  o f  u n la b e lle d  A 4  ad d ed  to  seru m  ex tra c te d  by  so lv en t w as 
in v estig a ted . A n d ro sten ed io n e  in e th an o l w as ev ap o ra ted  in  a series o f  
tu b es to  g ive  a ran g e  o f  25-125  nmol/1 in in c rem en ts  o f  25. T o  o n e  series 
w as added  fem ale  serum  (100  p i)  and to  an o th er m ale  serum . A n d ro sten ed io n e  
w as m easu red  in  a v o lu m e ( 2 0  p i)  o f  nea t and  sp iked  sam ples fo llo w in g  so lven t 
ex traction . R esu lts fo r the recovery  o f  added  unlabelled  A 4  ex tracted  by  solvent 
are  show n in  T ab le  20. M ean  reco v erie s  o f  A 4  added , in in c reasin g  am oun ts, 
to  serum  sam ples from  a w om an  and a m an w ere 98%  and  95 .5% , respectively .
4.2 .  P r e c i s i o n
F ig u re  14 illu s tra te s  a typ ica l s tandard  cu rv e  and  p rec is io n  p ro file  fo r  th e  serum  
R IA . T he  ran g e  o f  the standard  cu rv e  w as 1 to  21 nm ol o f  A 4  p e r  litre , as 
in terp o la ted  from  the p recision  p ro file  by  the m ethod  o f  M cC onw ay  e t al,153 i e 
th e  p o in ts  a t w h ich  the C V  w as < 22% . W ith in -b a tch  an d  b e tw e en -b a tc h  
p rec is io n  w ere  assessed . F o r q u ality  co n tro l poo ls , an d ro s ten ed io n e  w as added  
to  n o rm al m a le  seru m  to  g ive  co n cen tra tio n s  o f  ap p ro x im a te ly  3, 9, an d  16 
n m o l o f  A 4  p e r litre . A liq u o ts  w ere  sto red  fro zen  fo r up  to  6  m o n th s. T o  
d e te rm in e  w ith in -b a tch  p re c is io n , each  p o o l w as assa y ed  ten  tim e s  on  o n e  
o c c a s io n , th e  re su lts  w e re  a v e ra g e d  an d  th e  s ta n d a rd  d e v ia tio n  (S D ) an d  
co e ffic ien t o f  v a ria tio n  (C V ) w ere ca lcu la ted . T o  d e te rm in e  b e tw een -b a tch  
p re c is io n  each  p o o l w as assay ed  on 10  sep ara te  o ccas io n s  the re su lts  av e rag ed  
and  the  SD  and  C V  w ere  ca lcu la ted . T he w ith in - and  the b e tw een -b a tch  C V s 
w e re  co n s is te n tly  < 1 0 % fo r  lo w -, m ed iu m -, an d  h ig h -c o n c e n tra tio n  se ru m  
p o o ls .
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Table 20. Analytical recovery of androstenedione added to serum obtained 
from two normal adult volunteers.
A n d ro s te n e d io n e  (nm ol/1)
Added Determined Expected Recovery (%)
Fem ale 0 2.9
5 7.8 7.9 99
10 13.1 12.9 101
15 18.1 17.9 101
20 20.8 22.9 91
Male 0 1.9 *
5 6.3 6.9 91
10 10.7 11.9 90
15 18.0 16.9 107
20 20.8 21.9 95
1 0  ..I 1 - I  -  1 I , ■ - L  ■ . JL - 1 Q
0 . 5  5 . 5  1 0 . 5  1 5 . 5  2 0 . 5
A4 (nmol / l )
Fig. 14. A typical standard curve (-•-) and precision profile (-o-) for 
a serum RIA for androstenedione (A4 ). A4 was extracted from 
serum samples or evaporated from ethanolic standard solutions and 
incubated with antibody C and 125i_A4-3CMO label for 45 min at 
37 °C. After an overnight incubation with soluble second antibody 
at 4 °C , separation of bound and antibody-free A4 was obtained by 
centrifuging for 60 min at 4 °C  and discarding the supernatants. 
The percentages bound (B) and coefficient of variation (CV) were 
plotted against A4 concentration
M ea su rem en t o f  sam p les fro m  the U .K . N a tio n a l E x te rn a l Q u a lity  A sse ssm en t 
S chem e gave resu lts that com pared  w ell w ith those from  the o ther 15 partic ipa ting  
lab o ra to ries . D u rin g  six  m o n th s  the b ias w as + 12 .2%  and  the  v a ria b ility  o f 
b ias  w as 6 .9% .
A  ty p ica l s tandard  cu rve  and  p rec is io n  p ro file  fo r the  d irec t an d  ex trac tio n  b lood  
sp o t assays are  illu stra ted  by F ig . 15. F ro m  the p rec is io n  p ro files , the  ran g es 
o f  the  standard  cu rves fo r A 4 , ca lcu la ted  as above, w ere  5 -300  an d  4 -525  nmol/1, 
resp ec tiv e ly . B lood  spot quality  con tro ls w ere p rep ared  by  sp ik ing  a w ho le  b lood  
m atrix  w ith  an d ro sten ed io n e  to  g ive co n cen tra tio n s o f  25 , 50, 100, and  
200  nm ol o f  A 4  p e r litre. T o  d e term in e  w ith in -b a tch  p rec is io n , each  p o o l w as 
a ssay ed  tw en ty  tim es on one occasion , the resu lts  w ere av erag ed  and  the SD  and 
C V  w ere  ca lcu la ted . B etw een-batch  p recision  w as d e term in ed  by assay in g  each  
p o o l in  d u p lica te  on ten  separate  occasions, the re su lts  av e rag ed  and  the  SD  and  
C V  w ere  ca lcu la ted . T he m ean in terassay  C V s w ere  <16%  and  < 10% , and  
th e  m ean  in tra -a ssay  C V s w ere  <13%  an d  < 10%  fo r  the  d irec t and  
ex trac tion  m ethods, respectively , fo r b lood  spot contro ls.
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Fig. 15. A precision profile (-•-) with a typical standard curve (-0 -) for 
blood-spot A4 radioimmunnoassay measured a) directly in dried blood 
spots eluted from filter paper or b) after solvent extraction of the eluted 
blood. Dried blood-spot discs (5 mm) were eluted overnight into
saline. Ab C-7 and 125]_A4-3CMO label were incubated for 2 h at
22 °C  a) directly with the eluates and b) with A 4 extracted from the 
eluates. After an overnight incubation at 4 °C  with soluble second 
antibody, separation of antibody-bound and -free was obtained by 
centrifugation for 60 min at 4 °C and discarding the supernatants. The 
percentages binding and coefficient of variation (CV) were plotted against 
A4 concentration.































































4.3 .  P a r a l l e l i s m
P ara lle lism  o f  the d o se-resp o n se  re la tio n sh ip  fo r the s tan d ard  an d  th e  u n k n o w n  
in d ica te s  th a t a sam p le  re sp o n d s  in the  sam e w ay  o v e r the w o rk in g  ra n g e  as 
ana ly te  added  to  an analyte-free m atrix .
T o  a sse ss  p a ra lle lism , A 4  w as m easu red  in  se ru m  fro m  fo u r  p a tie n ts  w ith  
in c reased  A 4  co n cen tra tio n s  at various d ilu tions. S erum  sam ples w ere  d ilu ted  
1/2, 1/4, 1/8 and  1/16 w ith  R IA  buffer. A  v o lu m e o f  n ea t seru m  (20  p.1) 
an d  each  d ilu tio n  (20  (il) w as ex trac ted . B y  d ilu tin g  the  sam p le , the  ac tu a l 
v o lu m e  o f  se ru m  ex trac ted  w as 10, 5, 2 .5 and  1.25 fil. S im ila r v a lu es  fo r  all 
d ilu tio n s w ere o b ta in ed  i f  the concen tra tions fe ll w ith in  the lim its  o f  the standard  
cu rv e , as show n in  T ab le  21. T h ese  resu lts  su g g est lack  o f  in te rfe ren ce  fro m  
u n k n o w n  co m p o u n d s in serum  sam ples.
It w as n o t p o ss ib le  to  o b ta in  b lo o d  in su ffic ie n t v o lu m e  fro m  an in fan t w ith  
grossly  increased  A 4  (i.e. un trea ted  C A H ) to  assess p ara lle lism  in the b lood  spo t 
R IA s.
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Table 21. Parallelism Study: Measurement at different 
dilutions of sera from four patients with increased 
androstenedione concentrations.
P a t ie n t
S a m p le
d i lu t io n A B C D
U ndilu ted >21* >21 >21 12.3
1:2 22 .8 26.6 19.6 9 .5
1:4 2 2 .2 2 6 .0 2 1 .9 11.3
1:8 23.1 23 .5 2 1 .5 12.6
1:16 21.1 26.1 2 4 .5 9 .8
(*) All results expressed as nmol/1.
C H A P T E R  5. C L IN I C A L  E V A L U A T I O N  O F  T H E  
S E L E C T E D  S Y S T E M  U S E D  T O  M E A S U R E  A 4 IN  
H U M A N  S E R U M  A N D  B L O O D -S P O T  S A M P L E S
C o n cen tra tio n s  o f  A 4  w ere m easu red  in serum  and  in  b lood  spo ts u n d e r n o rm al 
and  patho log ical conditions.
5 . 1 .  C o n c e n t r a t i o n s  o f  A 4  i n  H u m a n  S e r u m
C o n cen tra tio n s  o f  A 4  in  serum  u n d er n o rm al an d  p a th o lo g ica l c o n d itio n s  are  
sh o w n  in  T ab le  22. T h e  sam ples fro m  n o rm al h ea lth y  ad u lt v o lu n tee rs  w ere  
co llec ted  betw een  0900  and 1700 hours. T here is no  sign ifican t d iffe rence in A 4  
v a lu es  fo r  m ales  and fem ales, bu t bo th  g roups show  a sig n ifican t red u c tio n  w ith  
ag e  (P  = 0 .0 3 2  an d  0 .0 0 9  fo r m ales  an d  fem a les , re sp e c tiv e ly ) . D iu rn a l 
v a ria tio n  in  a g roup  o f  six norm al adu lt m ale v o lu n teers  w as d em o n stra ted  by  a 
m a rk e d  ea rly  m o rn in g  p e a k  in  seru m  A 4  (F ig . 16). S ig n if ic a n tly  in c re a se d  
c o n cen tra tio n s  (P < 0 .001) w ere  found  in w om en  w ith  p o ly cy stic  o v a rian  d isease  
(T able 22). T hree  patien ts w ith  congenita l adrenal hyperp lasia  w ere  investigated  
w h o  h ad  u rin a ry  s te ro id  m e tab o lite  p ro file s  c o n s is te n t w ith  2 1 -h y d ro x y la se  
defic iency , and resu lts  from  serum  17-hydroxyprogesterone are in c lu d ed  fo r
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Table 22. Serum androstenedione concentrations in healthy 
adults and in patients with polycystic ovarian disease (PCO) 
or congenital adrenal hyperplasia (CAH).
S u b je c t n M e a n
A 4 (n m o l/I)
R a n g e  (X  ±  2 S D )
Norm al fem ales
18 - 40  years old 70 4.7 0 .6 -  8.8
4 1 - 6 5  years old 32 3.9 0 .9  - 6.8
Norm al males
18 - 40  years old 78 5.0 1 . 6 - 8 . 4
4 1 - 6 5  years old 21 3.9 1 . 2 - 6 . 6
PC O  fem ales 14 10.8 5 .0 -1 6 .7
CAH  patients  
U n trea ted  neonate 





12-year-old (inadequate replacem ent)
p re-rep lacem en t 104 
2-h post dose 82
(313)
(149)
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Fig. 16. Twenty-four-hour serum androstenedione profile: 
Androstenedione measured at hourly intervals in a group of six 
adult male volunteers. Results are represented as mean ±  S.E.M.
co m p ariso n  (T ab le  22). G ro ssly  in c reased  A 4  co n cen tra tio n s  w e re  fo u n d  in 
bo th  the  u n trea ted  n eo n a te  and  in the 1 2 -y e a r-o ld  w h o  w as re c e iv in g  s te ro id  
re p la cem e n t th erap y . T h e  la te -o n se t p a tien t w as a 3 6 -y ear-o ld  w o m an  w ho  
p resen ted  w ith increasing  h irsutism .
5 . 2 .  C o n c e n t r a t i o n s  o f  A 4  i n  B l o o d - S p o t  S a m p l e s
D ire c t an a ly sis  o f  A 4  w as p erfo rm ed  on  b lo o d -sp o t sam p les  co lle c te d  o n  filter- 
p a p e r  G u th rie  c a rd s  fro m  o n e  in fan t w ith  C A H , fro m  in fa n ts  b o m  a t te rm  
(n= 106) o r  p rem a tu re ly  (n = l 1 0 ) o r  w ith  re sp ira to ry  d is tress  sy n d ro m e (n = l  1). 
A lso  ca rried  o u t w as analysis o f  A 4  afte r so lven t ex trac tio n  o f  b lo o d  spots from  
p a tien ts  w ith  C A H  (n = 9 ), and  fro m  in fan ts  b o rn  a t te rm  (n = 8 5 ) o r  p re te rm  
(n = 90) o r  w ith  re sp ira to ry  d is tress  syndrom e (n= 18) (T ab le  23). T h e  n o rm al 
re fe re n c e  in te rv a ls  fo r A 4  fo r  in fan ts  b o m  at te rm  w ere  < 4 -2 2  an d  < 5 -8 8  
nmol/1 (99%  co n fid en ce  lim its), respective ly , w ith  o r w ith o u t so lv en t ex trac tio n . 
H ig h e r concen tra tions o f  A 4  w ere found  in the d irec t assay  than  in  the ex traction  
assay , w h ich  ind icates p o ssib le  in te rfe rence  from  stero id  co n ju g ates  th a t are  no t 
so lv en t ex trac tab le . In c reased  A 4  co n cen tra tio n s  w ere  fo u n d  in  som e sam ples 
fro m  in fa n ts  b o rn  p re m a tu re ly  o r  w h o  w e re  su ffe r in g  re s p ira to ry  d is tre s s  
syndrom e, in all cases o f  2 1 -hydroxy lase  defic iency , and  in  on e  case  o f  
11 (3 -hydroxy lase  d e fic ien cy . T h e  1 lp -h y d ro x y la s e  d e f ic ie n c y  re m a in e d  
u n d iag n o sed  un til the ch ild  re ach ed  the age o f  four, w h en  signs o f  p reco c io u s  
p u b e r ty  o ccu rred . In th is  case  A 4  w as m easu red  in  a f ilte r  p a p e r  b lo o d -sp o t 
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C H A P T E R  6. D IS C U S S IO N  and  C O N C L U S IO N S
T h e  p u rp o se  o f  th is  p ro je c t w as to  d e v e lo p  a rad io im m unoassay  fo r  th e  
m easu rem en t o f  an d ro sten ed io n e  in  sam ples o f  hum an  serum  and , in  p articu la r, 
neonata l d ried  b lood  spots to perm it the detection  and  hom e-m on ito ring  o f  in fan ts 
w ith  co n g e n ita l ad ren a l h y p e rp la s ia  d u e  to  2 1 - an d  11 (3 -h y d ro x y la s e  
defic iencies.
In itia lly , th e  a im  w as to  p ro d u c e  su itab le  a n tise ra  an d  I [ j ] - r a d i0 l a b e ls . 
A n tise ra  w ere  ra ised  in rab b its  ag a in st th ree  an d ro s ten ed io n e  d e riv a tiv e s , each  
c o n ju g a te d  to  p o s it io n  3, 6 o r  11 on  th e  s te ro id  n u c le u s . T h e n  th re e  
an d ro s te n ed io n e  ra d io lab e ls  w ere  p rep ared  by lin k in g  to
p o sitio n  3, 6 o r 11 on the stero id  nucleus. In  add ition , re ag en ts  eg . seco n d  
a n tib o d y  (so lu b le  an d  so lid -p h a se )  an d  m ic ro e n c a p su la te d  a n tib o d y  w e re  
p ro d u c e d  to  s e p a ra te  th e  a n tib o d y -b o u n d  fro m  th e  u n b o u n d  f ra c t io n  o f  
and rostened ione.
P rep a ra tio n  o f  spec ific  ste ro id -p ro te in  co n ju g a tes  w ere  b ey o n d  the  sco p e  o f  th is 
s tu d y  an d  lin k ag e  p o sitio n s  w ere  lim ited  to  3, 6 an d  11 by  the  av a ilab ility  o f  
co m m erc ia l m ateria l. S im ilarly , fo r the p rep ara tio n  o f  io d in a ted  s te ro id  labels , 
lin k ag e  p o s itio n s  w ere  a lso  lim ited  to  3, 6 and  11 by the av a ilab ility  o f  ste ro id  
deriva tives su itab le fo r conjugation  w ith iodohistam ine.
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F o llo w in g  an tib o d y  titre  ex p erim en ts, co m b in a tio n s o f  an tise ra  an d  rad io lab e ls  
w ere  in v es tig a ted  to  d e term in e  w hich  system s y ie ld ed  accep tab le  d o se-resp o n se  
cu rv es. T h o se  w h ich  d id  w ere  tes ted  fo r sen sitiv ity  an d  sp ec ific ity . T h en , 
u sin g  each  usefu l system , an d ro sten ed io n e  w as m easu red  in  serum  sam ples and  
th e  re su lts  co m p ared  w ith  the  ‘in -h o u se ’ m e th o d  em p lo y in g  a tr itia ted  tracer. 
T h e  b es t im m u n n o assay  w as d ev e lo p ed  fu r th e r to  m easu re  an d ro s ten ed io n e  in 
d ried  b lo o d  spots from  neonates, w ith  o r w ithou t so lven t ex traction . T h e  la tte r 
m e th o d  m ak es p o ss ib le  la rg e -sca le  screen ing  fo r an d  h o m e-m o n ito rin g  o f  C A H  
du e  to 21- and 11 (3-hydroxylase defic iencies.
T h e  fo llow ing  is a d iscussion  o f  the resu lts  found  in  th is study.
A  n u m b er o f  rep o rts  in  the lite ra tu re  c lea rly  in d ica te  th a t the  p o in t o f  lin k ag e  o f  
B S A  to  th e  s te ro id  n u c leu s  fo r the  im m u n o g en  an d  th e  lin k ag e  p o s itio n  o f  
io d o h is ta m in e  to  the s te ro id  label are  im p o rtan t co n sid era tio n s. A n tise ra  hav e  
b een  ra ise d  ag a in s t s te ro id s  lin k ed  to  p ro te in  th ro u g h  m an y  p o s itio n s  on  the  
s te ro id  nu cleu s . Id ea lly  the p o sitio n  o f  linkage shou ld  lack  a fu n c tio n a l g roup , 
ex p o se  both  ends o f  the m olecu le  154 ancj be  such  that the p ro te in  d o es no t sh ield  
p art o f  the steroid  m olecule. 155
In th is s tudy  it has been  c lea rly  illu stra ted  that linkage p o sitio n s o f  bo th  lab e l and  
im m unogen  can  have a dram atic  effec t on  assay perform ance. B o th  hom ologous 
(sim ilar linkage positions fo r label and im m unogen) and he tero logous (d ifferen t 
lin k ag e  p o sitio n s fo r label and im m unogen) system s w ere investiga ted . L in k ag e  
th rough  position  6 p rov ided  the least im m unogen ic conjugate.
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T h e  co m b in a tio n s  o f  an tise ra  and  tracers  s tud ied , d em o n stra ted  that, w ith  on e  
ex cep tio n  (A b C ), an tisera  d id  no t b ind  a trace r w hich  w as lin k ed  at a d iffe ren t 
p o sitio n  from  that o f  the im m unogen  i.e. h e tero logous system s. W hen  an tibody  
is d irec ted  ag a in st the bridge, as w ell as the stero id  m o lecu le  in  the im m u n o g en , 
and the sam e bridge is used in the tracer, the an tiserum  m ay have a h ig h er affin ity  
fo r lab e lled  s te ro id  than  u n lab e lled  stero id . T h is  p ro b lem  is k n o w n  as b rid g e  
reco g n itio n  and  re su lts  in the  fa ilu re  o f  u n lab e lled  ste ro id  to  d isp lace  lab e lled  
s te ro id  fro m  the  an tib o d y  b in d in g  site. F o r h o m o lo g o u s  sy stem s, in se n s itiv e  
s tan d ard  cu rv es , p o ss ib ly  re la ted  to  b rid g e  r e c o g n it io n , 156 w ere  fo u n d  in  the  
A 4 -6 PH S an d  tw o  o f  the th ree A 2 - I  lcxHS system s, ren d erin g  such  co m b in a tio n s 
im p rac tica l fo r  d ev e lo p m en t o f  b lood  spot assays. B rid g e  reco g n itio n  d id  not 
o c c u r  in  any  o f  th e  -3 C M O  h o m o lo g o u s  sy s tem s b ec au se  th e  A 4 - 3 C M O - 
io d o h is tam in e  rad io lig an d  w as d isp laced  from  an tisera  at low  A 4  con cen tra tio n s. 
T h ese  f in d in g s  su p p o rt the su g g estio n  o f  W ebb  et al 157 th a t b rid g e  b in d in g  
m ay  d ep en d  on the p o sition  o f  a ttach m en t to the stero id ; in te rfe ren ce  is m in im al 
w hen  p o sitio n  3 is used. In  fact, hom ologous system s have been  d esc rib ed  that 
a re  sen s itiv e  en o u g h  to  m easu re  s te ro id  h o rm o n e  c o n c e n tra tio n s  in  seru m , 
in c lu d in g  c o rtiso l,158 ll-d e o x y c o rtiso l,1 5 9  a ldosterone 160 and  testo sterone . 161 
H o w e v e r, in  th is  study , little  success w as o b ta in ed  w ith  h o m o lo g o u s  
sy stem s b ased  on an 1 1 -linkage , w hich  y ie lded  o n ly  on e  su itab le  co m b in a tio n  o f  
label and  an tibody  (A b I).
In  c ro ss-rea c tio n  stud ies, 5 a -a n d ro s ta n e -3 ,1 7 -d io n e  an d  1 ,4 -an d ro s tad ie n -
3 ,1 7 -d io n e  in te rfe re d  s ig n ifican tly  fo r a ll sy stem s tes ted . H o w e v e r h igh  
co n cen tra tio n s  o f  th ese  stero ids are  un likely  to  o cc u r in  serum  as they  
are p re sen t o n ly  as tran sito ry  m etabo lic  in term ed ia te s. 162 F o r ex am p le , 
even  in the hum an  testis, w here high concen tra tions o f  androgen  p recu rso rs  are 
p resen t, these  tw o  steroids w ere not detected  by gas ch ro m ato g rap h y -m ass
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s p e c t r o m e t r y .  1^3 S ign ifican t cross reac tio n  w ith  4 -a n d ro s te n -3 ,l 1 ,17-trione 
o ccu red  on ly  w hen an l ^ j . ^ - l l a H S  tracer w as used.
A ll an tise ra  tes ted  w ere  ab le  to  d iscrim in ate  w ell be tw een  a d o u b le  b o n d  and  
an y  o th e r  g roup  at p o sitio n  17 and  c ro ss  re ac ted  s tro n g ly  on ly  w ith  th o se  
ste ro id s w hich , like an d ro sten ed io n e , have d o u b le  bonds at p o s itio n s  3 and  17
i.e . 5 a -a n d ro s ta n -3 ,1 7 -d io n e , 1 ,4 -an d ro stad ien  3 ,1 7 -d io n e  an d  4 -a n d ro s ten -
3 ,1 1 ,1 7 -tr io n e . T h e  la s t  s te ro id  sh o w ed  h ig h  c ro ss  re a c t io n  w ith  th e  
m ic ro e n c a p su la te d  A b  C : 1 l a H S  h e te ro lo g o u s  sy s tem  an d  th e
m ic ro en cap su la ted  A b I : 1 2 5 j_ A 4 - l la H S  h o m o lo g o u s system , b u t no t w ith  
the  A 4 -3 C M O  h o m o lo g o u s system . It w as ex p ec ted  th a t a  h igh  c ro ss  reac tio n  
m ay  o ccu r w ith  the A 4 - I  lcxHS hom ologous system  as the bond  at p o s itio n -11 is 
the p o s itio n  o f  lin k ag e  in the co n ju g ate , and so y ie ld s  an tise ra  w h ich  are n o t 
specific  fo r that site.
L o w  c ro ss  reac tio n  w as ex h ib ited  by 5 (3 -an d ro stan -3 ,1 7 -d io n e  to  all b u t o n e  
(m icro en cap su la ted  A b  B) an tiserum . T h is  s te ro id  d iffe rs  in  shape fro m  5 a -  
an d ro s tan -3 ,1 7 -d io n e  w hich  exh ib its  h igh  cross reaction . T h e  h y d ro g en  a tom  
in the p -position  resu lts in a stero id  m olecu le w hich  is no  lon g er p lan ar and  hence 
p rev en ts  b in d in g  to  the  an tibody . W h ereas w hen  the h y d ro g en  a to m  is in  the  
a -p o s it io n ,  the  p lan e  o f  the  s te ro id  m o lecu le  is  m a in ta in ed  an d  b in d in g  is 
u nh indered . A  very  sm all d iffe rence in  the spatial co n fig u ra tio n  o f  a m o lecu le
can  g ive vastly  d iffe ren t resu lts w ith respect to  an tibody  binding . T hese  studies 
c lea rly  illu stra te  that the linkage p o sition  o f  bo th  the label and  an tib o d y  p lays an 
im portan t p art in  the specificity  o f  the assay system .
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T h e  m o st spec ific  assay , as gauged  by cross reac tio n  stud ies, w as o b ta in ed  w ith  
an tise ru m  ra ised  in rab b it A  ag a in st A 4 -3 -C M O -B S A  and  used  w ith  an  A 4 - 3 - 
C M O -io d o h is ta m in e  lab e l. In  p ra c tic e , h o w ev er, w h en  p a tie n ts ' se ru m  
sam ples w ere m easu red  w ith this com bination , they  w ere positive ly  biased.
T h e  developm en t o f  d irect, non-ex traction  assays fo r A4  m ay  be im peded  b y  the 
p re s e n c e  o f  in te rfe r in g  su b s ta n c e s  in  sam p le s . G o o d a ll  e t  a l  h av e  
d e m o n s tra te d  a h ig h  co n c e n tra tio n  o f  a c irc u la tin g  a n d ro s te n e d io n e  
c o n ju g a te . ^64 j n a p re lim in ary  study  o f  a d irec t A 4  assay , u sin g  the  se lec ted  
reag en ts , all serum  an d ro sten ed io n e  co n cen tra tio n s, d e te rm in ed  w ith o u t so lv en t 
ex tra c tio n , w e re  g ro ss  o v e r  es tim ates . T h is  su g g ests  th e  p re se n c e  o f  h ig h  
co n cen tra tio n s  o f  c ro ss-reac tin g , p o la r co n ju g ates o f  s tero ids. D irec t s te ro id  
R IA 's  h av e  been rep o rted  w here  re su lts  o b ta in ed  are  h ig h er than  th o se  o b ta in ed  
a fte r ex traction . In a serum  p rog este ro n e  assay, the in te rfe ren ce  is th o u g h t to  be 
du e  to  c ross reaction  w ith stero id  m etabo lites and con jugates. 165 S im ilarly , in 
th e  d ire c t  1 7 -h y d ro x y p ro g e s te ro n e  b lo o d  sp o t sc re e n in g  a ssa y , h ig h  c ro ss  
re a c tio n  w ith  a s te ro id  co n ju g a te  (i.e. 1 7 -h y d ro x y p reg n en o lo n e  su lp h a te ) w as
apparen t. 6 8
A n o th e r sou rce  o f  in te rfe ren ce  can  be the p resen ce  o f  sp ec ific  s te ro id  b in d in g  
p ro te in s  in  sam ples. Sex horm one b ind ing  g lobu lin  is a P -g lobu lin  capab le  o f  
b in d in g  a  v a rie ty  o f  an d ro g en s, in c lu d in g  an d ro s ten ed io n e , w ith  h ig h  a ffin ity . 
T ab le  24  show s the  re la tiv e  b ind ing  a ffin ities  and  asso c ia tio n  co n stan ts  o f  som e 
s te ro id s  b in d in g  to  S H B G  in  b lo o d  p lasm a. W ay s  o f  b lo ck in g  s te ro id
b in d in g  to  sp ec ific  b in d in g  p ro te in s  h av e  been  d esc rib ed . T h ese  in c lu d e  the  
ad d itio n  o f  ex cess  testo ste ro n e  16 6  ancj o e s tr a d io l^ 6 7  to  d isp lace  o es trad io l and  
tes to s te ro n e , re sp ec tiv e ly  fro m  S H B G , and  the use  o f  D a n a z o l ,1 6 8  l7 -p re g n -4 -  
en -20yno (2 ,3 -d )iso x azo l- 17-ol, an d  c o r t is o l16 9  t0  d isp lace  p ro g este ro n e  from
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Table 24. Relative binding affinities (RBA) of some steroids 
to sex hormone binding globulin.
S T E R O ID  R B A  (x lO ^ ) K a (106 m ol/1)
p rogesteron e 7.1 8.8
androstened ione 23 29
5-an d rosten ed io l 9 7 0  1500
testosteron e 1000  1600
dih yd rostestosteron e 2 2 0 0  5 5 0 0
(K a) A ffin ity  constant.
co rtico ste ro id  b in d in g  g lobulin . V arious m eth o d s, in c lu d in g  h ea t trea tm en t, 170 
low  pH , 171 low  pH  w ith  A N S 172  and s a l i c y l a t e ^  h ave  been  used  to d isp lace  
co rtiso l from  endogenous b ind ing  p ro teins. U sin g  the se lec ted  reagen ts  at a low  
p H  to  avo id  the possib le  p rob lem  o f  specific b ind ing  p ro te ins, d irec t 
m easu rem en t o f  A 4  in  serum  w as a ttem p ted  aga in . A s befo re , all seru m  A 4  
co n c en tra tio n s  w e re  g ross o v erestim a tes . L o w erin g  the  p H  d id  n o t im p ro v e  
the  d e p re sse d  b in d in g , w h ich  su g g es ts  th a t in te rfe re n c e  w as n o t cau sed  by  
specific  b ind ing  p ro te ins but cross-reacting  p o la r con jugates o f  steroids.
T h e  se le c te d  p ro c e d u re  fo r  se ru m  A 4 d e te rm in a tio n  g a v e  n o rm a l an d  
p a th o lo g ic a l v a lu e s  in  k eep in g  w ith  ea rlie r  rep o rts . 162  a  re d u c tio n  in  
c i rc u la t in g  A 4 a f te r  th e  age o f  4 0 , as re p o rte d  by  H u m m e r e t a l ,1 7 4  w as 
co n f irm e d . W h e th e r  g o n ad s  o r ad ren a ls  a re  the  so u rce  o f  th is  m a te r ia l is 
u ndecided , bu t H u m m er et a l repo rted  a sim ilar reduction  in age m atched  p re- and  
p o s t-m e n o p a u sa l w o m en , 174 w h ich  su g g ests  a  red u ced  ad ren a l ac tiv ity . O u r 
f in d in g  th a t red u c tio n  is s im ila r in  m ales  and  fem a les  w o u ld  su p p o rt th is  v iew . 
D e h y d ro ep ian d ro s te ro n e  su lp h a te , an an d ro g en  o f  ex c lu s iv e ly  ad ren a l o rig in , 
a lso  show s a s im ila r age re la ted  reduction . 175 F u rth erm o re , the la rg e  ad ren al 
co n trib u tio n  to  c ircu la tin g  A 4  co n cen tra tio n s  is in d ica ted  by  the  m ark ed  d iu rn a l 
v a r ia tio n . A n d ro g en  c o n c en tra tio n s  in  m a les  h av e  b een  re p o rte d  to  sh o w  a 
d iu rn a l p attern  176 bu t the d iffe rence o f  o v e r 100%  fo r A 4  fo u n d  in  th is study  is 
m o re  m arked  than  the 4 0  - 50%  change p rev iously  reported . 177
9 0
A  m ajo r p rac tica l p ro b lem  w ith  b lood spot assays is the id en tifica tio n  o f  su itab le  
m ateria l to  use fo r standards. O btain ing  a large vo lum e o f  hea lthy  neonata l b lood  
is im p o ssib le . In itia lly , b lood  fro m  an ad u lt fem a le  v o lu n te e r  w a s  u sed  and  
e n d o g e n o u s  a d re n a l a n d ro s te n e d io n e  p ro d u c tio n  w a s  s u p p re s s e d  a f te r  
d ex a m e th aso n e . W h en  such  s tan d a rd s  w e re  u sed , h o w e v e r, m ax im u m  
b in d in g  o f  label w as ob tained  not by  the zero  standard  bu t by  neonata l sam ples.
T he  situation  w as rectified  by using  ch arcoal-stripped  serum  as the base fo r b lood  
sp o t s tan d a rd s . C h a rc o a l-s tr ip p e d  seru m  h as b een  w id e ly  u se d  fo r  th e  
p re p a ra tio n  o f  s tan d ard s fo r ste ro id  assay s, e .g . co rtiso l an d  o es trad io l assays. 
T he  d isad v an tag e  o f  th is type  o f  m atrix  is that not o n ly  are stero ids rem o v ed , bu t 
se ru m  p ro te in s  are  p artia lly  d en a tu red  w h ich  p ro d u c es  a m a rk e d  re d u c tio n  in 
e lectro ly te , p ro tein  and lipid concentrations.
U n like  m easu rem en t o f  A 4  in serum , d irec t m easu rem en t w as possib le  w ith  the 
b lo o d -sp o t assay, u sing  the selected  reagents. T he range o f  A 4  co n cen tra tio n s  
in  e lu a te s  o f  b lo o d  sp o ts  co lle c te d  fro m  n o rm a l in fa n ts  b o rn  a t te rm  an d  
d e te rm in ed  by  R IA  afte r so lvent ex traction , w as sligh tly  h ig h er than  th a t found  
recen tly  by  E gan  et al i.e. 0 .6 -2 .7  nmol/1 w ho le  b lood  (equ iva len t to  1.2 - 5 .4 
nm ol/1 se r u m ). 178 A n d ro s ten ed io n e  co n c en tra tio n s  w ere  ra ise d  in  som e 
in fan ts  b o m  p rem atu rely  o r w ith  resp ira to ry  d istress syndrom e w h e th e r they  w ere 
m easu red  d irec tly  o r  a fte r so lven t ex traction . S im ilarly , p rev io u s stu d ies have 
fo u n d  e lev a ted  co n cen tra tio n s  o f  1 7 -h y d ro x y p ro g este ro n e  in  p la s m a ! 7 9  an d 
b lo o d  spo ts^S  from  such in fan ts. D irec t assays a lw ays g av e  h ig h e r v a lu es  fo r 
A 4  th an  e x tra c tio n  assay s; th is  w as  a lso  th e  e a r l ie r  e x p e rie n c e  in  th e  
d e te rm in a tio n  o f  1 7 -h ydroxyprogesterone in  n eona ta l b lo o d  s p o ts .6 8  R aised  
A 4  co n cen tra tio n s  w ere  fo u n d  in  all n eona ta l b lo o d  spo ts te s ted  fro m  cases  o f  
C A H .
9 1
O n the basis o f  the resu lts p resen ted , it w ould  be feasib le  to  screen fo r C A H  by 
d e te rm in in g  A 4  by  d irec t assay  and  then reassess  a fte r so lven t ex trac tio n  those  
sam ples g iv ing  high  values. T h is strategy  w as successfu lly  em p lo y ed  in  a 
p ilo t sc reen in g  study  in  S co tland  fo r C A H  usin g  1 7 -h y d ro x y p ro g este ro n e  
estim atio n s.^^  T he w ork ing  range o f  the A 4  assay  described , in  add ition  to  the 
su itab ility  o f  the b lood  spot specim en, is also  appropriate  fo r hom e m on ito ring  o f  
g lucocortico id  rep lacem en t therapy  in patien ts  w ith  C A H . S everal g roups have 
re c o m m e n d e d  th is  1 8 0 -1 8 2  b ecau se  w h en  se ru m  a n d ro g en s  w e re  s tu d ied  in  
ch ild ren  w ith  C A H  to  ev a lu a te  adequacy  o f  trea tm en t, A 4  w as show n to  re flec t 
b es t the  d eg ree  o f  con tro l. 103 C oncen tra tions o f  A 4  in  serum  can  be u sed  to
m o n ito r co n tro l in p a tien ts  o f  all ages 180,182 ancj qjq jess  a ffec ted  by  in d iv idua l 
s te ro id  d o ses  than  are 17 -hy d ro x y p ro g estero n e  m easu rem en ts . 183 O th ers  have  
d esc rib ed  the u se  o f  reag en ts  p ro d u ced  as p art o f  th is s tudy  in  h o m e  m o n ito rin g  
o f  g lucocortico id  rep lacem ent therapy in patien ts w ith  C A H . 178
T h e  se lec ted  reag en ts  desc rib ed , p ro v id e  a sensitive  sp ec ific , p rec ise , an d  ro b u st 
im m u n o assay . It has been  co n firm ed  th a t e lev a ted  c o n c en tra tio n s  o f  A 4 
o cc u r in u n trea ted  c lass ica l ca ses  o f  2 1 -h y d ro x y la se  d e fic ien cy  (and  
11 P -h y d ro x y lase  d efic iency ) and  are m odestly  ra ised  in la te -o n se t cases. S om e 
increase  m ay  also  o ccu r in  polycystic  ovarian  d isease  but fu rth e r tests, such as the 
r e s p o n s e  o f  A 4 a n d  1 7 -h y d ro x y p ro g e s te ro n e  to  S y n a c t h e n l 8 4  a n d /o r  
m easu rem en t o f  urinary  steroid m e ta b o lite s  185 are requ ired  to assist in  d ifferen tial 
d iag n o sis . T h e  sensitiv ity  o f  th is R IA  allow s A 4  to  be m easu red  in  a v ery  sm all 
v o lu m e  o f  sam p le  w h ich  fac ilita te s  n eo n a ta l sc reen in g  fo r  C A H  an d  h o m e 
m on ito ring  o f  the efficacy  o f  rep lacem ent therapy  by m easu rem en t o f  A 4  in  d ried
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blood  spots. T he m ajo r advan tages o f  A 4  o v er 17-hydroxyprogesterone 
determ inations are that C A H  due to 11 p -hydroxylase defic iency  can  be d iagnosed  
in  ad d ition  to  2 1 -hy d ro x y lase  d efic ien cy  and that it m ay  be a b e tte r in d ica to r o f  
efficacy  o f  g lucocorticod  rep lacem ent therapy.
O n e  r e s u l t  o f  th is  p ro je c t  w a s  th e  r e p la c e m e n t  o f  a c u m b e r s o m e  
rad io im m unoassay  fo r serum  androstened ione em p lo y in g  a tritia ted  rad io ligand . 
N o w  the m ethod  d escrib ed  in th is thesis  is u sed  fo r ro u tin e  d iag n o stic  p u rp o ses  
in  the Institu te  o f  B iochem istry , R oyal In firm ary , G lasgow .
U sin g  the an d ro s ten ed io n e  b lo o d -sp o t assay  d ev e lo p e d  fo r  th is  th es is , I h av e  
show n th a t an d rostened ione  is e leva ted  in  sam ples from  in fan ts  w ith  C A H  du e  to  
e i th e r  2 1 -h y d ro x y la se  d e f ic ie n c y  o r  11 p -h y d ro x y la se  d e f ic ie n c y . T h e  
ap p lica tio n  o f  th is  assay  to  m ass  n eo n a ta l sc reen in g  fo r  C A H  w o u ld  h av e  an  
im p o rtan t ad v an tag e  o v e r ex is tin g  p ro g ram m es. N ow  it is p o ss ib le  to  ex ten d  
screen in g  to  in c lu d e  the de tec tion  on C A H  due to  11 p -h y d ro x y lase  d efic ien cy  in  
addition  to  C A H  caused  by  21-hydroxy lase defic iency .
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